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(57) ABSTRACT 
The present invention involves a novel tripyrrole dimethine 
derived "expanded porphyrin” (texaphyrin), the synthesis of 
such compounds, their analogs or derivatives and their uses. 
These expanded porphyrin-like macrocycles are efficient 
chelators of divalent and trivalent metal ions. Metal com 
plexes of these compounds are active as photosensitizers for 
the generation of singlet oxygen and thus potentially for 
inactivation or destruction of human immunodeficiency 
virus (HIV-1), mononuclear or other cells infected with such 
virus and tumor cells as well. A variety of texaphyrin 
derivatives have been produced and many more are readily 
obtainable. Various metal (e.g., transition, main group, and 
lanthanide) complexes with the texaphyrin and texaphyrin 
derivatives of the present invention have unusual water 
solubility and stability which render them particularly use 
ful. These metallotexaphyrin complexes have optical prop 
erties making them unique as compared to existing porphy 
rin-like or other macrocycles. For example, they absorb light 
strongly in a physiologically important region (i.e. 690-880 
nm). These complexes also form long-lived triplet states in 
high yield and act as efficient photosensitizers for the 
formation of singlet oxygen. These properties, coupled with 
their high chemical stability and appreciable solubility in 
polar media such as water, add to their usefulness. 
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TEXAPHYRN MACROCYCLES AND METAL 
COMPLEXES THEREOF 
This application is a divisional application of Ser. No. 
07/871,357 filed Apr. 20, 1992, now U.S. Pat. No. 5,292, 
414. U.S. Ser. No. 07/871,357 was a divisional application 
of Ser. No. 07/771,393 filed Sep. 30, 1991, now abandoned. 
U.S. Ser. No. 771,393 was a continuation-in-part application 
of U.S. Ser. No. 07/539,975, filed Jun. 18, 1990 since issued 
as U.S. Pat. No. 5,162,509, and a continuation of PCT/ 
US90/O1208, filed Mar. 6, 1990, now abandoned. Ser. No. 
07/539,975 was a divisional application of 07/320,293 filed 
Mar, 6, 1989, since issued as U.S. Pat. No. 4,935,498. The 
application and the patents are incorporated by reference 
herein. 
The porphyrins and related tetrapyrrole macrocycles are 
among the most versatile of tetradentate ligands' (see 
Example 1 for the references in this paragraph). Attempts to 
stabilize higher coordination geometries, however, with 
larger porphyrin-like aromatic macrocycles have met with 
little success. Indeed, to date, only the uranyl complex of 
"superphthalocyanine' has been isolated and characterized 
structurally, although several other large porphyrin-like 
aromatic macrocycles, including the "sapphyrins", 
"oxosapphyrins'," "platyrins", "pentaphyrin', and "(26) 
porphyrin', 'have been prepared in their metal free forms. 
Although the porphyrins and related tetrapyrrolic com 
pounds remain among the most widely studied of all known 
macrocycles, relatively little effort has been devoted to the 
development of larger conjugated pyrrole containing sys 
tems'' (references cited in this paragraph are shown in 
Example 2). Large, or "expanded' porphyrin-like systems, 
however, are of interest for several reasons: They could 
serve as possible aromatic analogues of the better studied 
porphyrins' or serve as potential biomimetic models for 
these or other naturally occurring pyrrole-containing sys 
tems.'" In addition, large pyrrole containing systems offer 
exciting possibilities as novel metal binding macrocyles.” 
9-12, 15 For instance, suitably designed systems could act as 
versatile ligands capable of binding larger metal cations 
and/or stabilizing higher coordination geometries' than 
those routinely accommodated within the normally tetraden 
tate ca. 2.0 A radius porphyrin core.' The resulting com 
plexes could have important application in the area of heavy 
metal chelation therapy, serve as contrast agents for mag 
netic resonance imaging (MRI) applications, act as vehicles 
for radioimmunological labeling work, or serve as new 
systems for extending the range and scope of coordination 
chemistry. In addition, the free-base (metal-free) and/or 
diamagnetic metal-containing materials could serve as use 
ful photosensitizers for photodynamic therapeutic applica 
tions. In recent years a number of potentially pentadentate 
polypyrrolic aromatic systems, including the "sapphyrins', 
"oxosapphyrins", "smaragdyrins", platyrins, and 
"pentaphyrin” have been prepared and studied as their 
metal-free forms. For the most part, however, little or no 
information is available for the corresponding metallated 
forms. Indeed, the uranyl complex of 'superphthalocyanine' 
was the only metal-containing pentapyrrolic system which 
has been prepared and characterized structurally.” Unfortu 
nately, the "superphthalocyanine' system is apparently not 
capable of existence in either its free-base or other metal 
containing forms. Thus, prior to the present invention, no 
versatile, structurally characterized, pentadentate aromatic 
ligands were available,' although a number of nonaromatic 















Gadolinium(III) complexes derived from strongly bind 
ing anionic ligands, such as diethylenetriamine pentaacetic 
acid (DTPA), ''': 1,4,7,10-tetraazacyclododecane N,N',N.", 
N"-tetraacetic acid (DOTA),' and 1,10-diaza-4,7,13,16 
tetraoxacyclooctadecane-N,N'-diacetic acid (dacda), are 
among the most promising of the paramagnetic contrast 
currently being developed for use in magnetic resonance 
imaging (MRI) (references cited in this paragraph are 
shown in Example 3). Indeed, GdoDTPA is now under 
going clinical trials in the United States for possible use in 
enhanced tumor detection protocols. Nonetheless, the syn 
thesis of other gadolinium(III) complexes remains of interest 
since such systems might have greater kinetic stability, 
superior relaxivity, or better biodistribution properties than 
the existing carboxylate-based contrast agents. One 
approach currently being pursued is based on using water 
soluble porphyrin derivatives, such as tetrakis(4-sul 
fonatophenyl)porphyrin (TPPS)''' Unfortunately, the large 
gadolinium(III) cation cannot be accommodated com 
pletely' within the relatively small prophyrin binding core 
(rs2.0 A'), and, as a consequence, gadolinium prophyrin 
complexes are invariably hydrolytically unstable.7,8,12,13 
Larger porphyrin-like ligands, however, might offer a means 
of circumventing this problem.’ 
Acquired immunodeficiency syndrome (AIDS) and can 
cer are among the most serious public health problems 
facing our nation today. AIDS, first reported in 1981 as 
occurring among male homosexuals,' is a fatal human 
disease which has now reached pandemic proportions (the 
references in this and the following four paragraphs are 
shown in Example 5). Cancer, in spite of some very signifi 
cant advances in diagnostics and treatment in recent years, 
remains the third leading cause of death in this country. 
Finding better ways to detect, treat, and reduce the trans 
mission of these disorders are thus research objectives of the 
highest importance. 
One of the more promising new modalities currently 
being explored for use in the control and treatment of tumors 
is photodynamic therapy (PDT). This technique is based 
on the use of a photosensitizing dye, which localizes at, or 
near, the tumor site, and when irradiated in the presence of 
oxygen serves to produce cytotoxic materials, such as sin 
glet oxygen (O,(A)), from otherwise benign precursors 
(e.g. (O.(2)). Much of the current excitement associated 
with PDT derives from just this property: In marked contrast 
to current methods (e.g. conventional chemotherapy), in 
PDT the drugs themselves can (and should) be completely 
innocuous until "activated” with light by an attending phy 
sician. Thus a level of control and selectivity may be attained 
which is not otherwise possible. 
At present, diamagnetic porphyrins and their derivatives 
are considered the dyes of choice for PDT. It has been 
known for decades that porphyrins, such as hematoporphy 
rin, localize selectively in rapidly growing tissues including 
sarcomas and carcinomas, although the reasons for this 
selectivity remain recondite. Currently most attention is 
focusing on the so-called hematoporphyrin derivative 
(HPD),’’’ an incompletely characterized mixture of 
monomeric and oligomeric porphyrins produced by treating 
hematoporphyrin dihydrochloride with acetic acid-sulfuric 
acid followed by dilute base.'" Fractions rich in the 
oligomeric species, which are believed to have the best 
tumor-localizing ability,' are marketed under the trade 
name Photofirin II(E) (PII) and are currently undergoing 
phase III clinical trials for obstructed endobronchial tumors 
and superficial bladder tumors. Here, the mechanism of 
action is thought to be largely, if not entirely, due to the 
5,587,463 
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photoproduction of singlet oxygen (O,(A)) although alter 
native mechanisms of action, including those involving 
superoxide anion or hydroxyl and/or porphyrin-based radi 
cals cannot be entirely ruled out.” Promising as HPD is, 
it and other available photosensitizers (e.g., the phthalocya 
nines and napthaphthalocynines) suffer from serious disad 
vantages. 
While porphyrin derivatives have high triplet yields and 
long triplet lifetimes (and consequently transfer excitation 
energy efficiently to triplet oxygen), their absorption in 
the Q-band region often parallels that of heme-containing 
tissues. Phthalocyanines and naphthalocyanines absorb in a 
more convenient spectral range but have significantly lower 
triplet yields; moreover, they tend to be quite insoluble in 
polar protic solvents, and are difficult to functionalize. Thus 
at present the development of more effective photochemo 
therapeutic agents appears to require the synthesis of com 
pounds which absorb in the spectral region where living 
tissues are relatively transparent (i.e., 700-1000 nm), have 
high triplet quantum yields, and are minimally toxic. The 
present inventors have recently reported (see Example 1) 
the synthesis of a new class of aromatic porphyrin-like 
macrocycles, the tripyrroledimethine-derived "texaphyrins", 
which absorb strongly in the tissue-transparent 730-770 nm. 
range. The photophysical properties of metallotexaphyrins 
1-7 parallel those of the corresponding metallaporphyrins 
and the diamagnetic complexes 1-4 sensitize the produc 
tion of 'O in high quantum yield. FIG. 19 shows the 
schematic structure, metal complexes and derivatives of 
compounds of the present invention (1-7). 
Singlet oxygen is also believed to be the critical toxic 
species operative in experimental photosensitized blood 
purification procedures.' This very new application of 
photodynamic therapy is of tremendous potential impor 
tance: It shows promise of providing a safe and effective 
means of removing enveloped viruses such as HIV-1, herpes 
simplex (HSV), cytomegalovirus (CMV), various forms of 
hepatitis-inducing virus, as well as other opportunistic 
blood-borne infections (e.g. bacteria and malaria plasmo 
dium) from transfused whole blood. Given that AIDS is 
currently a not effectivley treated and usually fatal disease, 
the benefit of such a blood purification procedure would be 
of inestimable value. 
At present, sexual relations and needle-sharing are the 
dominant mechanisms for the spread of AIDS. An increas 
ing percentage of AIDS infections, however, are now occur 
ring as a result of blood transfusions.'" Unfortunately, 
banked blood components are essential products for the 
practice of modern medicine and as a result this method of 
transmission is not likely to be precluded by simple changes 
in lifestyle. Rather, an absolutely fail-proof means must be 
developed to insure that all stored blood samples are free of 
the AIDS virus (and ideally all other blood-borne patho 
gens). To a certain extent this can be accomplished by 
screening the donors' histories and carrying out serologic 
tests. At present, however, the serologic tests for HIV-1 are 
insufficient to detect all infected blood samples, in particular, 












but not yet produced detectable antibodies.'" In addition, 
new mutants of the AIDS virus have been detected; some or 
all of which may escape detection by current means. Thus, 
an antiviral system is needed which removes any form of 
HIV-1 from stored blood. This is particularly important 
since a stored blood sample from one infected donor could 
potentially end up being administered to several different 
patients, in, for instance, the course of pediatric care. 
The present invention involves a novel tripyrrole dime 
thine-derived "expanded porphyrin” (texaphyrin), the syn 
thesis of such compounds, their analogs or derivatives and 
their uses. These expanded porphyrin-like macrocycles are 
efficient chelators of divalent and trivalent metal ions. Metal 
complexes of these compounds are effective as photosensi 
tizers for the generation of singlet oxygen and thus poten 
tially useful for the inactivation or destruction of tumors as 
well as for the prophylactic treatment and removal of human 
immunodeficiency virus (HIV-1), and other viral contami 
nants from blood. A variety of texaphyrin derivatives have 
been produced and many more are readily obtainable. Vari 
ous metal (e.g., lanthanide) complexes with the texaphyrin 
and texaphyrin derivatives of the present invention have 
unusual water solubility and stability which render them 
particularly useful. These metallotexaphyrin complexes 
have optical properties making them unique as compared to 
existing porphyrin-like or other macrocycles. For example, 
they absorb light strongly in a physiologically important 
region (i.e. 690-880 nm). Certain diamagnetic complexes 
also form long-lived triplet states in high yield and act as 
efficient photosensitizers for the formation of singlet oxy 
gen. These properties, coupled with their high chemical 
stability and appreciable solubility in polar media such as 
water, add to their usefulness. 
The present invention relates to a class of compounds 
related to the basic compound having the structure: 
wherein R is H or CH. This compound has been prepared 
as one having the structure: 
  
5,587,463 
wherein M is H, L is absent and n is 0; or M is Cd, L is 
pyridine or benzimidazole and n is 1. 
A preferred compound of this invention is a cadmium 
texaphyrin complex having the structure: 
A variety of texaphyrin derivatives and their metal con 
plexes have been prepared and may be characterized as 










wherein M is H, R is H and n is 0; M is Cd', R is H and 
n is 1; M is Nd", R is H and n is 2; M is Sm", R is H and 
n is 2; M is Eu", R is H and n is 2; M is Gd, R is H, and 
n is 2; M is Y, R is H, and n is 2; M is In", R is H, and 
n is 2; M is Zn, R is H and n is 1; M is Hg", R is H, and 
n is 1. M is H, R is CH and n is 0; M is Gd", R is CH and 
n is 2; M is Eu', R is CH and n is 2; M is Sm', R is CH 
and n is 2; M is Y, R is CH and n is 2; or M is Int, R 
is CH and n is 2. 
The present invention also includes a compound which 
may be described as having the structure: 
i 
R 
wherein M is Zn, R and R' are H and n is 1; M is Zn, R 
is H, R is Cl and n is 1; M is Cd, R and R' are H and n is 
1; M is Cd, R is H, R is Cl and n is 1; M is Mn, R and R' 
are H, and n is 1; M is Sm, R and R' are CH and n is 2; M 
is Eu, RandR are CH and n is 2; or M is Gd, RandR are 





In a broader view, the present invention involves a com 
pound having the structure: 
wherein R and R' are CH; R is H and R' is OCH; R is H 
and R is Cl; R is H and R is COOH or R is Hand R' is NO; 
and wherein M is a divalent metal ion and n is 1, or M is a 
trivalent metal ion and n is 2. 
In another view the texaphyrin and its derivatives and 
complexes thereof of the present invention have the struc 
ture: 
wherein M is a divalent metal ion and n is 1, or M is a 














A particularly interesting texaphyrin analog of the present 
invention is one having the structure: 
wherein M is a divalent metal ion and n is 1, or M is a 
trivalent metal ion and n is 2. In the above-described 
metallic complexes M may be a divalent metal ion selected 
from the group consisting of Ca", Mn, Co, Ni, Zn', 
Cd', Hg, Sm' and UO'', (and n is 1) In certain aspects 
M is preferably Cd" or Zn' or Hg. When M is a trivalent 
metal ion, it is preferably selected from the group consisting 
of Mn, Co, Mn", Ni3, Y, In, Pr', Nd, Sm', 
Eut, Gd", Tb"3, Dy", Er"3, Tm3, Yb'-3, Lu, and U+3; 
(and n is 2.) Most preferred trivalent metal ions are In", 
Y, Nd, Eu", Sn and Gd. 
Additionally, the compounds of the present invention may 
be described as having the structure: 
I 
wherein RandR are F; R is Hand R' is O(CH2CH2O)CH; 
R is H and R' is SO; or R is H and R' is CO and M is 
a divalent metal ion and n is 1 or M is a trivalent metal ion 






A particularly preferred texaphyrin-derived compound is derivatives of the present invention. So also is a compound 
one having the structure: having the structure: 
f 
wherein M is a divalent metal ion and n is , or M is a wherein M is a divalent metal ion and n is 1 or M is a 
trivalent metal ion and n is 2. trivalent metal ion and n is 2. 
In another aspect, the present invention involves a com- 25 In yet another view, the present invention includes a 








wherein RandR are Hor CH and M is Hg', Cd, Co' 
or Mn, and n is 1; or M is Ln, Gd, Y or In and n 
wherein M is a divalent metal ion and n is 1; or M is a is 2; or R is H, R is C, Br, NO, COH or OCH M is 




Absent metal ions, compounds of the present invention 
may have the structure: 
or the structure: 
For example, a method for the synthesis of pentadentate 
expanded porphyrin compound is an aspect of the present 
invention. This method comprises synthesizing a diformyl 
tripyrrane; condensing said tripyrrane with an ortho aryl 
diamine 1,2-diaminoalkene or 1,2-diaminoalkane; and oxi 
dizing the condensation product to form a pentadentate 
expanded porphyrin compound. A preferred 1,2-diaminoalk 
ene is diamisomaleonitrile. The ortho aryldiamine is pref 
erably ortho phenylenediamine or a substituted orthophe 
nylenediamine. Another preferred ortho aryldiamine is 2,3- 
diaminonapthalene. Such a pentadentate expanded 
porphyrin compound is complexed with a metal and wherein 
a metal complex is produced by reaction of the pentadentate 
expanded porphyrin compound with metal ions. 
The present invention also involves a method of deacti 
vating retroviruses and enveloped viruses in blood. This 
method comprises adding a pentadentate expanded porphy 
rin analog metal complex as described above to blood and 
exposing the mixture to light to facilitate the formation of 
singlet oxygen. 
Photodynamic tumor therapy comprising administering a 
pentadentate expanded porphyrin analog complexed with a 
metal to a tumor host and irradiating the analog in proximity 













A method for MRI enhancement comprising administer 
ing a diamagnetic metal ion (such as gadolinium, for 
example) complexed with texaphyrin or a texaphyrin deriva 
tive is also an aspect of the present invention. 
FIG. 1A and FIG. 1B show a schematic structural view of 
Texaphyrin (1) and various complexes (2, 3 and 4). 
FIG. 2 shows a view of complex 4 (from FIG. 1A and 
FIG. 1B) showing pyridine and macrocycle coordination to 
Cd. Ellipsoids scaled to the 40% probability level. The Cd 
ion lies in the plane of the nearly planar macrocycle (maxi 
mum deviation from planarity 0.10 (1) A). Relevant Cd-N 
bond lengths (A) are as follows: 2.418(7), N1; 2.268(8), N8; 
2.505(7), N13; 2.521(7), N20; 2.248(8), N23; 2.438(14), 
N1a; 2.473(12), N1b. Selected N-Cd-N bond angles 
(deg) are as follows: N1-Cd-N8, 78.9(2); N1-Cd-N23, 
80.2(3); N8-Cd-N13, 68.4(2); N13-Cd-N20, 64.4(2); N20 
Cd-N23, 68.2(3); N1a-Cd-N1b, 176.1 (4). 
FIG. 3 shows a view of complex 4 perpendicular to the 
plane through the macrocycle. Pyridine rings (not shown) lie 
perpendicular to the macrocycle with dihedral angles of 88.5 
(4) for ring a and 89.1 (3)o for ring b. 
FIG. 4A, FIG. 4B, FIG. 4C, and FIG. 4D shows a 
schematic representation of the reduced (1) and oxidized 
(2) forms of the free-base "texaphyrin' and representative 
five, six, and seven coordinate cadmium complexes (3-5A) 
derived from this “expanded porphyrin'. 
FIG. 5 shows a view of the cation 5 showing pyridine 
and macrocycle coordination to Cd. Ellipsoids are scaled to 
the 30% probability level. The cadmium(II) cation lies in the 
plane of the nearly planar macrocycle (max. deviation from 
planarity, 0.10(1) A). Relevant Cd-N bond lengths (A) are: 
2.418(7) N1; 2.268(8) NS; 2.505(7) N13; 2.521 (7) N20; 
2.248(8) N23; 2.438(14) N1a; 2.473(12) N1b. Selected 
N-Cd-N bond angles () are: 78.9(2) N1-Cd-N8; 80.2(3) 
N1-Cd-N23; 68.4(2) N8-Cd-N13; 64.4(2) N13-Cd-N20; 
68.2(3) N20-Cd-N23; 176.1 (4) N1a-Cd-N1b. For further 
structural details, see ref. 11. 
FIG. 6 shows a view of cation 4 showing the atom 
labelling scheme. Thermal ellipsoids are drawn to 30% 
probability level. Relevant Cd-N bond lengths (A): N1 
2.462(13); N8 2.254(9); N13 2.535(13); N20 2.526(12); 
N23 2.298(11); N1A 2.310(9). Selected N-Cd-N bond 
angles (): N1-Cd-N8 78.3(4); N8-Cd-N13 67.8(4); N13 
Cd-N20 64.1(4); N20-Cd-N23 67.3(4); N1A-Cd-macro 
cycle N angles range from 93.7(4) to 100.4(3). The nitrate 
counter anion (not shown) is not coordinated to the Cd atom. 
FIG. 7 shows a view along the plane through the macro 
cycle illustrating the face-to-face stacking of the cation 4A 
in the unit cell (macrocycle realted by 1-x,y,z). The macro 
cycle mean planes are separated by 3.38 A while the CdCd 
distance is 4.107(1) A. 
FIG. 8 shows a view of cation 4 perpendicular to the 
plane through the macrocycle (max. deviation 0.154(13) A 
for C15). The Cd atom lies out this plane by 0.334(2) A. 
BzIm (not shown) is oriented nearly perpendicular to the 
macrocycle (dihedral angle of 86.3(3)) and lies over the 
pyrrole ring defined by C22, N23, C24, C25, and C26. 
FIG. 9A and FIG. 9B shows a UV-visible spectrum of 
3oNO, 1.50x10M in CHCl, 
FIG. 10A and FIG. 10B shows "H NMR spectrum of 
3AONO in CDCl3. The signals at 1.5 and 7.26 ppm represent 
residual water and solvent peaks respectively. 
FIG. 11 shows a low field region of the H NMR spectra 
(in CDCl) of 3ONO (spectrum A) and the bulk inhomo 
geneous material from which crystals of complex 4bAONO 
were isolated (spectrum B). The signals marked "BzIm’ 
ascribed to the bound benzimidazole ligand are observed at 
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6.4., 6.81, and 7.27 ppm; the signals marked 's are due to 
residual solvent. 
FIG. 12 shows H NMR spectral titration of 3ONO 
(initially 6.85x10M in CDC) with increasing quantities 
of Bzlm showing moderate field region. The BzIm/ 
ligand ratios are 0,0.2,0.6, 2.8, 10, and 40 for traces A 
through Frespectively, where BzIm) and ligand represent 
the total molar concentration of added benzimidazole and 
starting five-coordinate complex 3AoNO. The chemical 
shifts for the BzIm signals in curve C (6.4, 6.62, 7.26 ppm) 
match well with those seen in the bulk sample from which 
the crystal of cation 4b was isolated (c.f. spectrum B of 
FIG. 11). 
FIG. 13 shows the H NMR spectral titration of 3ONO, 
(initially 6.85x10M in CDCl) with increasing quantities 
of BzIm showing changes occurring in high field region. The 
BzIm)/ligand) ratios are 0, 0.2,0.6, 2.8, 10, and 40 for 
traces A through Frespectively, where BzIm) and ligand) 
represent the total molar concentration of added benzini 
dazole and starting five-coordinate complex 3ONO 
FIG. 14 shows changes in the "H NMR chemical shift of 
the “meso" signal for 3oNO plotted as a function of 
increasing BzIm). The terms BzIm) and ligand) represent 
the total molar concentration of added benzimidazole and 
starting five-coordinate complex 3AONO. 
FIG. 15 shows H NMR spectral titration of 3 oNO 
(initially 6.66x10M in CDC) with increasing quantities 
of pyridine showing changes occurring in high field region. 
The pyr/ligand) ratios are 0, 5, 10, 14, 20, and 40 for 
traces A through Frespectively. The terms pyr and ligand 
represent the total molar concentration of added benzimi 
dazole and starting five-coordinate complex. 
FIG.16 shows changes in the H NMR chemical shift of 
the "meso" signal for 3AONO as a function of increasing 
(pyr). The terms pyr and ligand) represent the total molar 
concentration of added benzimidazole and starting five 
coordinate complex 3ONO. 
FIG. 17A and FIG. 17B show metal complexes and 
derivatives (1-11) of compounds of the present invention. 
FIG. 18A and FIG. 18B show the electronic spectrum of 
2OOH) in CHCl. 
FIG. 19 schematically shows the structure, metal com 
plexes and derivatives of compounds of the present inven 
tion (1-11). 
FIG. 20A shows the absorption spectrum of complex 
1OCl in deoxygenated methanol. FIG. 20B shows the fluo 
rescence emission spectrum recorded in this same solvent. 
FIG. 21A shows the triplet-triplet transient difference 
spectrum of 10Cl in deoxygenated methanol recorded 1 us 
after irradiation with a 10 ns pulse of 355 nm light (80 m.J). 
FIG. 21B shows the rate of return to ground state, as 
monitored at 480 nm, and corresponds to a triplet lifetime of 
67 us. 
FIG. 22 shows the spectral transmittance through human 
abdominal wall with a thickness of 22-32 mm' (reference 
47 taken from Example 5). 
FIG. 23A, FIG. 23B, FIG. 23C, and FIG. 23D show 
schematic structures of previously developed prophyrin 
derivatives potentially useful as photosensitizers. These 
include purpurins (1); verdins (2), benz-fused porphyrins 
(3); and sulfonated phthalocyanines and napthylocyanines 
(4). 
FIG. 24A, FIG. 24B, FIG. 24C, FIG.24D, and FIG.24E 
show schematic structures of texaphyrin (5); sapphyrin 
(6), platyrin (7); vinylogous porphyrin (8); and por 
phycenes (9). 
FIG. 25A, FIG. 25B, and FIG. 25C show schematic 
structures of new aromatic tripyrroledimethine-derived mac 















FIG. 26A and FIG. 26B schematically (scheme 1) sum 
marizes the synthesis of texaphyrin (5). 
FIG. 27A, FIG. 27B, FIG. 27C, and FIG. 27D show 
schematic structures of extant and proposed texaphyrin 
derivatives (23–30). 
FIG. 28A and FIG. 28B show schematic structures of 
proposed methine-linked texaphyrin derivatives (31 and 
32). 
FIG. 29 shows mononuclear cell killing by complexes 1 
and 3 without irradiation. Cell kill was determined by 
3H-Thy uptake after phytohemagglutin (PHA) stimula 
tion. 
FIG. 30 shows mononuclear cell killing by 1 g/ml 
complex 3A and irradiation. Cell kill was determined by 
H-Thy uptake after PHA stimulation. 
FIG. 31A, FIG. 31B, and FIG. 31C show expanded 
porphyrin-like macrocycles on hand. Alternatively to the 
pyrrolic hydrogen, a di- or trivalent cation such as Cd', 
Zn', In", etc. may be bound. In this case, the complex 
could bear a net overall charge, i.e. +1 for M' and +2 for 
M+3. 
The present invention involves the synthesis of a novel 
"expanded porphyrin” system, 1 (to which the trivial name 
"texaphyrin” has been assigned), and includes description of 
the structure of the bispyridine adduct of its cadmium(II) 
complex. The presence in this structure of a near circular 
pentadentate binding core which is roughly 20% larger than 
that of the porphyrins, coupled with the realization that 
almost identical ionic radii pertain for hexacoordinate Cd" 
(r=0.92 A) and Gd" (r=0.94 A),’ prompted exploration of 
the general lanthanide binding properties of this new 
monoanionic porphyrin-like ligand. The synthesis and char 
acterization of a water-stable gadolinium(III) complex 
derived formally from a new 16,17-dimethyl substituted 
analogue of the original "expanded porphyrin' system, as 
well as the preparation and characterization of the corre 
sponding europium(III) and samarium(III) complexes. 
The aromatic "expanded porphyrin' system described 
herein provides an important complement to the existing 
rich coordination chemistry of porphyrins. For instance, by 
using methods similar to those described, zinc(II), manga 
nese(II), mercury(II), and neodymium(III) complexes have 
been prepared and characterized. 
The photophysical properties of this new series of tripyr 
roledimethine-derived "expanded porphyrins' ("texaphy 
rins') are reported; these compounds show strong low 
energy optical absorptions in the 690-880 nm spectral range 
as well as a high triplet quantum yield, and act as efficient 
photosensitizers for the production of singlet oxygen, for 
example, in methanol solution. 
The present invention involves a major breakthrough in 
the area of ligand design and synthesis namely synthesis of 
the first rationally designed aromatic pentadentate macro 
cyclic ligand, a tripyrroledimethine-derived "expanded por 
phyrin'. This compound, to which the trivial name "texa 
phyrin' has been assigned, is capable of existing in both its 
free-base form and of supporting the formation of hydro 
lytically stable 1:1 complexes with a variety of metal 
cations, such as Cd", Hg, In, Y", Nd, Eu", Sm', 
and Gd", that are too large to be accommodated in a stable 
fashion within the 20% smaller tetradentate binding core of 
the well-studied porphyrins. In addition, since the free-base 
form of texaphrin is a monoanionic ligand, the texaphyrin 
complexes formed from divalent and trivalent metal cations 
remain positively charged at neutral pH. As a result, many 
of these complexes are quite water soluble-at least far 
more so than the analogous porphyrin complexes. 
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The results to date, some of which are summarized herein, 
indicate strongly that the expanded porphyrin-like macro 
cycles of the present invention should be efficient photosen 
sitizers for the destruction of free HIV-1 and for the treat 
ment of tumors in vivo and infected mononuclear cells in 
blood. Altering the polarity and electrical charges of side 
groups of these macrocycles is anticipated to alter markedly 
the degree, rate, and perhaps site(s) of binding to free 
enveloped viruses such as HIV-1 and to virally-infected 
peripheral mononuclear cells. These substituent changes are 
also expected to modulate photosensitizer take-up and pho 
tosensitization of leukemia or lymphoma cells contaminat 
ing bone-marrow as well as by normal cells of the marrow. 
EXAMPLE 1. 
The porphyrins and related tetrapyrrole macrocycles are 
among the most versatile of tetradentate ligands.' Attempts 
to stabilize higher coordination geometries, however, with 
larger porphyrin-like aromatic macrocycles have met with 
little success.” Indeed, to date, only the uranyl complex of 
"superphthalocyanine' has been isolated and characterized 
structurally,” although severe other large porphyrin-like aro 
matic macrocycles, including the "sapphyrins','"oxosap 
phyrins',” “platyrins”, “pentaphyrin', and “26porphy 
rin',' have been prepared in their metal free forms. This 
example describes one aspect of the development of a new 
type of "expanded porphyrin” capable of binding a variety 
of metal cations. Also described herein is the original 
synthesis of compound''' an unprecedented porphyrin-like 
aromatic pentadentate ligand,’’’ and the structure of its 
cadmium (II) bispyridine complex 4. (See FIG. 1A and FIG. 
1B for the structure of compound or complex 1-4) 
The present involves preparation of the nonaromatic 
methylene-bridged macrocycle (compound 1) by the direct 
acid-catalyzed condensation of 2,5-bis(3-ethyl-5-formyl-4- 
methylpyrrol-2-yl)methyl)-3,4-diethyl-pyrrole and ortho 
phenylenediamine' and determined it to be an ineffective 
cheland.' The present inventors have now found that stir 
ring the reduced macrocyclic compound 1 with cadmium 
chloride for 24 hours in chloroform-methanol (1:2 v.v.) in 
the presence of air, followed by chromatographic purifica 
tion on silica gel and recrystallization from chloroform 
hexanes, gives the cadmium(II) complex 3OCl in 24% yield 
as a darkgreen powder." Under the reaction conditions both 
ligand oxidation and metal complexation take place spon 
taneously. 
The structure of compound 3 suggests that it can be 
formulated as either an 18 TC-electron benzannelated 18 
annulene or as an overall 22 TC-electron system; in either case 
an aromatic structure is defined. The proton NMR spectrum 
of complex 3OCl is consistent with the proposed aromaticity. 
For the most part, complex 3OCl shows ligand features 
which are qualitatively similar to those observed for com 
pound 1. As would be expected in the presence of a strong 
diamagnetic ring current, however, the alkyl, imine, and 
aromatic peaks are all shifted to lower field. Furthermore, 
the bridging methylene signals of compound 1 (at 824.0)' 
are replaced by a sharp singlet, at 11.3 ppm, ascribable to the 
bridging methine protons. The chemical shift of this "meso” 
signal is greater than that observed for Cd(OEP) (8210.0), 
an appropriate 18 TC-electron aromatic reference system, 
and is quite similar to that observed for the free-base form 
of decamethylsapphyrin (8:11.5-11.7), a 22 at-electron 
pyrrole-containing macrocycle. 
The optical spectrum of complex 3OCl bears some resem 














rocyles and provides further support for the proposed 
aromatic structure. The dominant transition is a Soret-like 
band at 424 nm (e=72,700), which is considerably less 
intense than that seen for Cd(OEP)(pyr)' =421 nm, 
e=288,000). This peak is flanked by exceptionally strong 
N- and Q-like bands at higher and lower energies. As would 
be expected for a larger TC system, both the lowest energy 
Q-like absorption (=767.5 nm, e=41,200) and emission 
(=792 nm)) bands of complex 3oC are substantially 
red-shifted (by ca. 200 nm) as compared to those of typical 
cadmium porphyrins.'' 
When the above metal insertion was repeated with cad 
mium nitrate, a complex was obtained in roughly 30% yield, 
which, on the basis of microanalytical data," was formu 
lated as the protonated complex 3ONOO(HNO). Upon 
treatment with excess pyridine and recrystallization from 
chloroform-hexane, the bis-pyridine adduct complex 4-NO, 
with spectral properties essentially identical with 30Cl, was 
isolated as dark green crystals.' The molecular structure of 
4-NO, determined by X-ray diffraction analysis, confirms 
the aromatic nature of the ligand (FIG. 2).'The central five 
nitrogen donor atoms of complex 4 are essentially coplanar 
and define a near circular cavity with a center-to-nitrogen 
radius of ca. 2.39 A (cf. FIG. 3), which is roughly 20% larger 
than that found in metalloporphyrins.' The Cd atom lies in 
the plane of the central N binding core. The structure of the 
"expanded porphyrin' 4 thus differs dramatically from that 
of CdTPP’ or CdTPP-(dioxane), in which the cad 
mium atom lies out of the porphyrin N donor plane (by 0.58 
and 0.32 A, respectively). Moreover, in contrast to cadmium 
porphyrins, for which a five-coordinate square-pyramidal 
geometry is preferred and to which only a single pyridine 
molecule will bind,' in complex 4-NO, the cadmium atom 
is seven-coordinate, being complexed by two apical pyridine 
ligands. The configuration about the Cd atom is thus pen 
tagonal bipyrimidal; a rare but not unknown geometry for 
cadmium(II) complexes.’ 
Under neutral conditions complexes 3 and 4 appear to be 
more stable than cadmium porphyrins: Whereas treatment of 
CdTPP or CdTPP(pyr) with aqueous Na2S leads to cation 
loss and precipitation of CdS, in the case of complexes 3 and 
4 no demetallation takes place. (Exposure to aqueous acid, 
however, leads to hydrolysis of the macrocyle.) Indeed, it 
has not been possible to prepare the free-base ligand 2 by 
demetallation. The tripyrroledimethine-derived free-base 
ligand 2 was synthesized directly from 1 by stirring in 
air-saturated chloroform-methanol containing N,N,N'-tet 
ramethyl-1,8-diaminonaphthalene.' Although the yield is 
low (s.12%),' once formed, compound 2 appears to be 
quite stable: It undergoes decomposition far more slowly 
than compound 1.' Presumably, this is a reflection of the 
aromatic stabilization present in compound 2. A further 
indication of the aromatic nature of the free-base "expanded 
porphyrin' 2 is the observation of an internal pyrrole NH 
signal at 8=0.90, which is shifted upfield by over 10 ppm as 
compared to the pyrrolic protons present in the reduced 
macrocyle 1.' This shift parallels that seen when the 
sp-linked macrocycle, octaethylporphyrinogen (8(NH)= 
6.9),” is oxidized to the corresponding porphyrin, H2OEP 
(6(NH)=-3.74).' This suggests that the diamagnetic ring 
current present in compound 2 is similar in strength to that 
of the porphyrins. 
The aromatic "expanded porphyrin” system described 
herein provides an important complement to the existing 
rich coordination chemistry of porphyrins. For instance, by 
using methods similar to those described, zinc(II), manga 
nese(II), mercury(II), and neodymium(III) complexes of 
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EXAMPLE 2 
Although the porphyrins and related tetrapyrrolic com 
pounds remain among the most widely studied of all known 
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macrocycles,' relatively little effort has been devoted to the 
development of larger conjugated pyrrole containing sys 
tems.’’ Large, or "expanded” porphyrin-like systems, 
however, are of interest for several reasons: They could 
serve as possible aromatic analogues of the better studied 
porphyrins’ or serve as potential biomimetic models for 
these or other naturally occurring pyrrole-containing sys 
tems.''' In addition, large pyrrole containing systems offer 
exciting possibilities as novel metal binding macrocyles.” 
9-12, 15 For instance, suitably designed systems could act as 
versatile ligands capable of binding larger metal cations 
and/or stabilizing higher coordination geometries' than 
those routinely accommodated within the normally tetraden 
tate ca. 2.0 A radius porphyrin core.' The resulting com 
plexes could have important application in the area of heavy 
metal chelation therapy or as new vehicles for extending the 
range and scope of coordination chemistry.'" In recent 
years a number of potentially pentadentate polypyrrolic 
aromatic systems, including the "sapphyrins", "oxosap 
phyrins", "smaragdyrins”, “ platyrins, and "pentaphy 
rin" have been prepared and studied as their metal-free 
forms. For the most part, however, little or no information is 
available for the corresponding metallated forms. Indeed, 
the uranyl complex of "superphthalocyanine' was the only 
metal-containing pentapyrrolic system which has been pre 
pared and characterized structurally. Unfortunately, the 
"superphthalocyanine' system is apparently not capable of 
existence in either its free-base or other metal-containing 
forms.' Thus, prior to the present invention, no versatile, 
structurally characterized, pentadentate aromatic ligands 
were available,' although a number of nonaromatic pyri 
dine-derived pentadentate systems had previously been 
reported.' The aspect of this invention described here 
further shows development of a new class of pyrrole-derived 
aromatic "expanded porphyrins' capable of binding a vari 
ety of metal cations and stabilizing a range of unusual 
coordination geometries. The present inventors have 
recently communicated the synthesis of compound 2A, '' 
(see Example 1) an unprecedented porphyrin-like monoan 
ionic aromatic pentadentate ligand to which has been 
assigned the trivial name "texaphyrin' (for large Texas-style 
porphyrin), and the structure of its seven coordinate cad 
mium(II) bispyridine pentagonal bipyramidal complex 5a. 
Due to the importance of cadmium complexes in possible 
chelation based therapeutic applications' and as potential 
structural probes for natural metalloproteins (e.g. employing 
'Cd NMR spectroscopy),’ the coordination properties of 
the cadmium-containing "texaphyrin' system were investi 
gated further. The present example reports the characteriza 
tion by single crystal X-ray diffraction analysis of a mono 
ligated six coordinate cadmium(II) benzimidazole 
pentagonal pyramidal cationic complex 4b corresponding 
formally to a coordinatively unsaturated analogue of 5a. 
The present description, which includes the results of solu 
tion base binding (K) studies for both pyridine (pyr) and 
benzimidazole (BzIm), constitutes the first structurally 
documented instance wherein the same macrocyclic ligand 
has been used to support these two rare, but not unknown,' 
coordination geometries about the same metal cation.' See 
FIG. 4A, FIG. 4B, FIG. 4C, and FIG. 4D for the schematic 
structure of compounds and complexes of the present inven 
tion referred to here as 1A, 2A, 3, 4a, 4b, 5a and 5ba. 
Treatment of the reduced, sp form of the macrocyle 
(1a)' with cadmium chloride or cadmium nitrate in air 
saturated chloroform-methanol leads in both cases to the 
formation of green solutions. Following chromatographic 













form-hexanes, the five-coordinate "texaphyrin” chloride or 
nitrate complexes 3.0Cl and 3AONO were obtained in 
analytically pure form (as the demihydrates) in roughly 25% 
yield. When, however, the metal insertion procedure was 
carried out (using cadmium nitrate) under reaction and 
purification conditions identical to those described above, 
with the exception that chromatography was effected on 
SEPHADEX, a mixture of crystalline and noncrystalline 
green solids was obtained. Treatment of this apparently 
inhomogeneous bulk material, which failed to analyze as a 
pure five coordinate complex, with excess pyridine and 
recrystallization from chloroform-hexanes produced the 
bispyridine complex 5a-NO as dark green crystals in 
essentially quantitative yield. As communicated earlier,' 
(see Example 1) an X-ray crystal diffraction analysis served 
to confirm the pentagonal bipyramidal coordination geom 
etry postulated for this bisligated seven coordinate complex 
and the planarpentadentate nature of the macrocyclic "texa 
phyrin' ligand 2A (c.f. FIG. 5). 
As a first step towards determining the nature of above 
intermediate product, a single crystal was isolated from the 
inhomogeneous solid mixture and subject to an X-ray dif 
fraction analysis. The structure so obtained (FIG. 6) was 
quite unexpected: It revealed a six coordinate pentagonal 
pyramidal cadmium(II) complex (4boNO) wherein one of 
the two possible axial ligation sites is occupied by a bound 
benzimidazole (BzIm) with the nitrate counter anion not 
being coordinated to the central Cd atom. The first donor 
nitrogens of the pentadentate "texaphyrin' macrocycle then 
serve to complete the coordination sphere about cadmium. 
As shown in FIG. 6, the 5 donor atoms of the ligand are 
bound to the Cd atom which lies out of the plane of the 
macrocycle being displaced by 0.338(4) A from the N 
donor plane towards the coordinated nitrogen of the benz 
imidazole ligand This out of plane distance, which is similar 
to that seen in CdTPP-(dioxane), (0.32 A)' (but smaller 
than that observed in CdTPP”), is in marked contrast to that 
observed for the corresponding bispyridine pentagonal bipy 
ramidal adduct 5a-NO.' In this earlier structure, the 
cadmium(II) cation was found to lie essentially within the 
plane of macrocycle (c.f. FIG. 5). Cation 4b further differs 
from 5a in that, within the crystal lattice, two molecules 
stack on one another in a face-to-face fashion (FIG. 7) being 
separated by van der Waals' distances of ca. 3.38 A. As a 
result, the alkyl groups in any given molecule are all 
displaced to the BzIm-bearing side of the macrocyclic plane. 
In common with the bispyridine structure,' however, in 
cation 4b, the sp” atoms of the macrocycle are all essentially 
planar (FIG. 8) with the maximum deviation from planarity 
(0.154(13) A) being found for C11. Also in common with 
complex 5a-NO, the five ligand nitrogens define a near 
circular binding cavity with a center-to-nitrogen radius of ca. 
2.42 A, which is roughly 20% larger than that found in 
metalloporphyrins. 
The above structural results support the original formu 
lation of "texaphyrin' 2 as a large 22 at-electron (or 
benzannelated 18 TL-electron) aromatic porphyrin-like 
ligand.’ They also clearly demonstrate that this "expanded 
porphyrin' is capable of supporting more than one kind of 
"unusual' coordination geometry about cadmium. 
The above structural results also provide insight into the 
nature of the inhomogeneous cadmium-containing interme 
diate obtained following metal insertion and sephadex-based 
purification: At least a portion of this material consists of the 
six-coordinate BzIm ligated complex 4b AoNO. Although it 
is certainly plausible to postulate that the coordinated BzIm 
in cation 4ba derives from ligand degradation reactions 
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associated with metal insertion and accompanying oxidation 
(presumably involving electrophilic aromatic deacylation of 
an tripyrrane O-carbon and subsequent condensation with 
ortho-phenylene diamine), the observation of this six-coor 
dinate species does not establish unambiguously that such 
BzIm coordination is chemically reasonable. This point is of 
particular interest since in the presence of excess pyridine, 
it is the bisligated seven coordinate cationic species 5a 
which is favored in the solid state. It was believed to be of 
importance to determine the solution binding properties of 
compound 3ONO in the presence of both benzimidazole 
and pyridine. The objective was not only to probe the 
ligation differences (if any) of these two axial bases but also 
to define further the nature of the intermediate inhomoge 
neous solid material formed following Cd insertion and 
SEPHADEX-based purification, testing in particular the 
reasonable assumption that this material consists of a mix 
ture of the five and six coordinate cations 3A and 4b. 
For a rigorously five coordinate starting cadmium com 
plex, such as that represented schematically by structure 3, 
where neither the counter anion nor adventitious ligands 
serves to occupy an apical coordination site, base binding 
can be considered to occur in accord with equations (1) and 
(2) shown below. Under conditions where K2K2, these 
processes can be considered to occur sequentially, giving 
first a monoligated, presumably pentagonal pyramidal six 
coordinate species (such as 4b), followed by a coordina 
tively saturated bisligated pentagonal bipyramidal product 
akin to 5a. Where, however, K22>K this stepwise con 
ceptual approach is invalid. Under these conditions, it 
becomes easier to analyze the base binding in terms of direct 
formation of the bisligated material as shown in equation 
(3). 
L+B LB K=(LBMLB (1) 
LB+B LB K=LBMLBB) (2) 
In the context of the present study therefore the problem 
becomes one of finding a solution-based analytical method 
that will allow changes associated with mono and bis 
ligation to be probed, and using the accompanying changes 
to determine as appropriate K1, K2, or KK2. 
Optical spectroscopy is an important method of charac 
terization for nonlabile metal complexes. In cases where 
absorption changes accompany ligand binding, optical spec 
troscopy also provides a convenient means of determining 
base binding constants.” In the case of cadmium tetraphe 
nyl porphyrin (CdTPP), for instance, Miller and Dorough,' 
by monitoring the changes associated with the two low 
energy Q bands of the absorption spectrum, determined a 
value for the binding of a single pyridine axial ligand to the 
unligated four-coordinate starting metalloporphyrin in ben 
zene at 29.9 (K) of roughly 2,700 M'. Interestingly, 
these' and later workers obtained no evidence for the 
formation of a bisligated CdTPP-(pyr) species. Thus, 
although a pseudo octahedral coordination geometry is 
defined in the solid state by the weakly bound axial ligands 
of CdTPP-(dioxane), here is no evidence that such a 
structure is attained in pyridine-containing benzene solution. 
The optical spectrum of purified complex 3AoNO (FIG. 
9A) bears some elements in common with that of cadmium 
porphyrins.'" For instance, complex 3ONO in CHCl 
displays a strong Soret-like high energy transition at 425 nm. 
(e=82,800) which is considerably less intense than that seen 














v/v 1%)=406 nm, e=272,000). This complex also displays 
exceptionally strong flanking N- and Q-like bands at higher 
and lower energy. The lowest energy Q-like band (M=770 
nm, e=49,800) is particularly noteworthy: It is shifted to the 
red by ca. 200 nm and is almost a factor of four more intense 
than the lowest energy Q-type transition seen in typical 
cadmium porphyrins (e.g. CdOEP: (CHCla/MeOH v/v 
1%)=571 nm, e=15,400). We consider such behavior to be 
reflective of the larger delocalized aromatic system present 
in the overall 22 TC-electron "texaphyrins' than in the 18 
TL-electron porphyrins. Interestingly, the lowest energy tran 
sition seen in the cadmium complex of 3,8,12,13,17.22 
hexaethyl-2,7,18,23-decamethylsapphyrin in CHCl is 701 
nm, whereas that seen for the uranyl complex of "super 
phthalocyanine" is 914 nm.” Thus the lowest energy tran 
sition of 3AoNO lies intermediate in energy between those 
observed for these two very different 22 TC-electron pentapy 
rrolic reference systems. 
Unfortunately, in spite of the gross qualitative resem 
blance between the optical spectrum of 3AONO and the 
other pyrrole-containing aromatic macrocycles described 
above, optical spectroscopy has proved to be an ineffective 
means of determining the axial ligation properties of cation 
3A. For instance, addition of excess pyridine to a solution of 
3AONO in CHCl caused only a ca. 1.5 nm red shift in the 
Soret-like band and a 3.5 nm blue shift of the lowest energy 
Q-type band. (Similar insignificant changes are also 
observed upon BzIm addition.) Thus, at least in the case of 
the cadmium complexes, the optical properties of the "texa 
phyrin' expanded porphyrin system appear to be largely 
determined by the overall macrocyclic skeleton and rela 
tively insensitive to changes in the electron environment of 
the bound cation. 
Cadmium(II) complexes of "texaphyrin' 2 are diamag 
netic and hence readily susceptible to study by "H NMR 
methods. As shown in FIG. 10, the H NMR of 30NO, 
shows general features which are typical of those expected 
for a large aromatic pyrrole-containing macrocycle. For 
instance, as compared to the sp form of the ligand (1)' the 
alkyl, imine, and aromatic peaks are all shifted to lower 
field. Even more diagnostic, however, are the presence of 
"meso" signals ascribable to the bridging sp’ hybridized 
methine protons in both the free base "texaphyrin' 2 and its 
various cadmium containing derivatives 3-5. These bridging 
protons resonate at ca. 7 ppm lower field than the corre 
sponding bridging methylene signals of the original sp form 
of the ligand (1a).' In fact, the “meso" signals of 3AoNO, 
is found roughly 1 ppm down field from those of typical 
3-alkyl substituted cadmium porphyrins (e.g. Cd(OEP),' 
8-10.0) and approach in value the chemical shifts observed 
for diamagnetic sapphyrins (e.g., for free-base decamethyl 
sapphyrine, 8:11.5-11.7). Such observations are not unex 
pected in light of the highly delocalized it character postu 
lated for the 22 TC-electron "texaphyrin” systems. 
FIG. 11 provides a comparison of the low field region of 
the 'HNMR spectra of 3AONO and the crude material from 
which the crystals of cation 4b were obtained. The most 
striking difference between these two spectra is the presence 
of a small broad signal at ca. 6.4 ppm and two sharper, more 
pronounced peaks at 6.81 and 7.27 ppm in the spectrum of 
the bulk material (trace B in FIG. 11). Although it is 
tempting to assign these features as signals arising from 
bound Bzim present in cation 4ba, this conclusion is not 
necessarily obvious: The carbon-bound protons of free BzIm 
in CDCl resonate at 7.25 (m, 2H), 7.75 (m, 2H), and 8.41 
(s, 1H) ppm. Although shifts to higher field is expected on 
binding to cation3, it is not clear that the expected changes 
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would be as large as those actually observed. A complete 
spectral titration of complex 3.NO with BzIm was there 
fore undertaken in an effort to address this matter and to 
assign unambiguously the 6.4., 6.81, and 7.27 ppm signals. 
The results of these titrations are given in FIGS. 12 and FIG. 
13. 
A striking feature of the "H NMR titration shown in FIG. 
12 is the dramatic change in chemical shift that occurs for 
the BzIm signals upon complexation to cation 3A. Equally 
important, however, is the observation that the qualitative 
features of the bulk cadmium containing material discussed 
above (c.f. FIG. 11, spectrum B) are reproduced upon the 
addition of roughly 3/3 equivalents of BzIm to purified 
3AoNO! This dramatic result provides, in our estimation, 
unambiguous support for the structural assignment of cation 
4b made on the basis of X-ray diffraction analysis. It also 
confirms qualitatively the original supposition that the inho 
mogeneous material isolated after Cd insertion and Sepha 
dex purification does indeed involve an admixture of five 
and six coordinated species (i.e. 3. ONO and 4boNO). 
For quantitative K determinations it proved easiest to 
monitor the changes associated with the "meso' signals. 
Here, sharp peaks, indicative of fast ligand exchange,' 
and reasonably large changes in chemical shift were 
observed (FIG. 13). In addition, no interfering BzIm-based 
resonances are found in this region. In FIG. 14 the changes 
in chemical shift for the "meso" protons in complex 3AoNO 
are plotted as a function of added BzIm. The resulting 
titration curve shows, that at least for this base, axial ligation 
can be considered as occurring in two essentially indepen 
dent stepwise binding processes. Standard analysis of the 
data at both very low and very high conversion gave values 
of K=1.8+0.2x10' and K=13+3. 
Just as was the case for BzIm, addition of pyridine to the 
five coordinate complex 3-vo gave rise to easily detected 
and well-defined changes in the chemical shift of the "meso' 
signals (FIG. 15). In marked contrast to the results obtained 
with BzIm, however, ligation in this case cannot be consid 
ered to be occurring in a discrete stepwise manner. This is 
quite apparent from an inspection of FIG. 13 in which the 
changes in chemical shift for the "meso' protons in complex 
3ONO are plot as a function of increasing pyridine con 
centration. Analysis of this binding isotherm using standard 
methods then gave values of K=1.6M and KK= 
315-30M. 
The above K and K2 (or KK) values are predicated on 
the assumption that the cadmium complexes under discus 
sion are stable with regards to demetallation and that the 
equilibria of equations l and 2 (or 3) pertain under the 
conditions of base binding. The first of these concerns is 
readily apparent: If demetallation occurs, then obviously one 
is not studying base binding All control experiments, how 
ever, suggested that the cadmium complexes derived from 
the "texaphyrin' ligand are many orders of magnitude more 
stable than those of the considerably smaller porphyrins. In 
fact, demetallation does not occur even when the complexes 
are challenged with excess sulfide anion (which serves to 
demetallate CdTPP''); it thus appears unlikely that such 
a process will occur in the presence of pyridine or benzimi 
dazole. The second concern is particularly important within 
the context of quantitative work: If, for instance, the starting 
complex 3ONO is not rigorously five coordinate, then K 
(and perhaps K as well) would represent an axial ligand 
displacement reaction rather than a pure addition process as 
implied above. Control experiments indicate that the 
assumption of initial five coordination is reasonable: Inde 














cate that only modest and monotonic changes in the chemi 
cal shift of the “meso' signals take place over the course of 
adding 250 equivalents of these potentially adventitious 
ligands.' This means that either "complete" binding occurs 
at 1:1 stoichiometry (essentially ruled out in the case of HO 
on the basis of analytical data), or that these species are 
poorly coordinating in CHCl, so that five coordination 
pertains about cadmium; the latter interpretation appearing 
more likely. 
To the extent that the above assumptions are valid, the 
K values obtained for BzIm and pyr binding in solution 
provide an accurate reflection of the coordination behavior 
observed in the solid state. For instance, at the concentra 
tions used for the "H NMR titration experiments (ca. 5x10 
3M) complex 3 eNO will be roughly 20% converted to the 
six coordinate form (4boNO) following the addition of 
only 0.2 molar equivalents of BzIm, and 90% converted 
after the addition of 1.0 molar equivalent. Interestingly, even 
in the presence of 10 molar equivalents, the resulting mono 
ligated species 4b will only be 35% converted to the 
corresponding bisligated seven coordinate form (5b). Thus 
for benzimidazole a large concentration range pertains in 
solution wherein in the monoligated cationic complex 4b is 
the dominant species. The equilibrium data also showed, 
however, that in solution it will always be either the bisli 
gated species 5a or unligated starting complex 3 which 
dominates in the presence of excess pyridine. For instance, 
under the conditions of the H NMR titrations, complex 
3AoNO will be roughly 5% converted to pentagonal bipy 
ramidal product 5a-NO after the addition of 3 equivalents 
of pyridine and roughly 35% converted to this species after 
the addition of 10 equivalents. 
Both steric and electronic factors may be invoked to 
explain the different ligation properties for pyridine and 
benzimidazole. Considerable work with metalloporphyrins, 
particularly in the context of heme model chemistry,' has 
served to establish the stronger coordinating abilities of 
imidazole type ligands relative to pyridine-type bases, an 
observation that is generally ascribed to the poorer Tt basicity 
of the latter systems.' Thus the high K value (relative 
to pyridine) observed for BzIm binding to cation 3A comes 
as little surprise. What is more puzzling, however, is the 
observation that K for this base is so low: At first glance it 
appears unreasonable that monoligation would be stable in 
the presence of this stronger Tt base since preferential 
conversion to the coordinatively saturated seven coordinate 
species occurs in the presence of pyridine. An inspection of 
the crystal structure shown in FIG. 6, however, provides the 
basis for an explanation: The BzIm residue lies nearly 
perpendicular to the macrocycle in 4b and is oriented over 
the pyrrole ring containing N23. As a result, H8A of the 
BzIm base is in close proximity to several atoms of this ring, 
making close contacts (A) with N23 (2.65(2)), C24 
(2.69(2)), and C22 (2.81(2)). Thus, as has been well-docu 
mented in the case of heme models and encumbered imi 
dazoles,' steric hindrance appears to be the fundamental 
factor favoring 6-coordination in the presence of excess 
BzIm. Thus both steric and electronic effects serve to 
differentiate the ostensibly very different binding behavior 
of BzIm and pyr in the present "expanded porphyrin' 
system. Such effects also provide interalia a rationale for the 
formation and selective isolation, in the solid state, of 
complexes 4boNO and 5aaoNO. 
The pentadentate 22 TC-electron porphyrin-like "texaphy 
rin' macrocycle is an effective and versatile ligand for 
cadmium(II). It is capable of supporting the formation of 
three rare coordination geometries for this cation, namely, 
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pentagonal, pentagonal pyramidal, and pentagonal bipyra 
midal. Whereas the first of these forms is currently only 
inferred on the basis of analytical and solution phase studies, 
the latter two geometries have been characterized both in 
solution and in the solid state by single crystal X-ray 
diffraction analyses. The "texaphyrin” system thus repre 
sents, to the best of our knowledge, the first structurally 
documented system capable of supporting both pentagonal 
pyramidal and pentagonal bipyramidal geometries about the 
same central metal cation. This unique cheland also endows 
these cadmium complexes with several other important 
properties. These include an optical spectrum with an unusu 
ally low energy Q-type band, and a stability with regards to 
demetallation which far exceeds that of the corresponding 
cadmium(II) porphyrins. The first of these properties sug 
gests that the present "texaphyrin' (2A) or other "expanded 
porphyrin' systems should find important application in the 
areas of photodynamic therapy or photosynthetic modelling 
studies where low energy absorption properties would be 
beneficial.' The second property suggests that systems 
similar to those presently described might provide the basis 
for the development of effective chelation-based detoxifica 
tion therapies for cadmium, a metal presently ranking only 
behind mercury and lead in toxicological importance,' and 
one for which few if any, therapies currently exist.' 
Electronic spectra were recorded on a Beckman DU-7 
spectrophotometer. Proton and 'C NMR spectra were 
obtained in CDCl using CHCl (6=7.26 ppm for 'H; 77.0 
ppm for 'C) as an internal standard. Proton NMR spectra 
were recorded on either Nicolet NT-360 (360 MHz), or 
General Electric QE-300 (300 MHz) spectrometer. Carbon 
spectra were measured at 125 MHz using the Nicolet 
NT-500 spectrometer. Fast atom bombardment mass spec 
trometry (FABMS) was performed using a Finnigan-MAT 
TSQ-70 instrument and 3-nitrobenzyl alcohol as the matrix. 
Elementary analyses were performed by Galbraith Labora 
tories. X-ray structures were solved as described below and 
in references 11 and 14. 
All solvents and reagents were of reagent grade quality, 
purchased commercially, and used without further purifica 
tion. Sigma lipophilic Sephadex (LH-20-100) and Merck 
type 60 (230-400 mesh) silica gel were used for column 
chromatography. The p form of the ligand (1A) was pre 
pared in 290% yield using the acid catalyzed method 
described earlier. The currently higher yield does not 
derive from a fundamental change in procedure but simply 
reflects a greater experience with this particular key reaction. 
Preparation of 4,59,24-tetraethyl-10,23-dimethyl-13,20, 
25,26.27-pentaazapentacyclo (20.2.1.1.1.0''') hep 
tacosa-1,3,5,7,9,11(27), 12, 14,16,18,20,22 (25),23-tride 
caene, free-base "texaphyrin” 2. Macrocycle 1A (50 mg, 
0.1 mol) was stirred in methanol/chloroform (150 ml, w/v2/1) 
in the presence of N,N,N',N'-tetramethyl-1,8-diaminonaph 
thalene ("proton sponge') for one day at room temperature. 
The reaction mixture was then poured into ice water. The 
organic layer was separated and washed with aqueous 
ammonium chloride solution and then brine. Following 
concentrations on a rotary evaporator, the crude material 
was purified by chromatography on SEPHADEX using first 
pure chloroform and then chloroform/methanol (v/v/1%) as 
eluents. After several faster redbands were discarded, a dark 
green band was collected, concentrated in vacuo, and recrys 
tallized from chloroform/n-hexane to give the sp’ form of 
the ligand as a dark green powder in yields ranging from 
3-12% with the better yields only being obtained on rare 
occasions. For 2: 'H-NMR (CDC1): 8=0.90 (1H, bris, 













3.42-3.58 (8H, m, CHCH), 8.25 (2H, m, phen. CH), 9.21 
(2H, s, CH=N, 9.45 (2H, m, phen. CH), 11.25 (2H, s, C 
H=C); C.I. MS (CH): 491 (calcd for CHNOH: 490); 
FAB MS (3-nitrobenzyl alcohol matrix, 8 keV acceleration): 
m/e 512 (calcd for CHNNa": 512) IR (KBr) v=3420, 
2960, 2920, 2860, 1600, 1560, 1540, 1370, 1350, 1255, 
1210, 1080, 1050, 980, 940, 905, 750 cm; UV/VIS 
(CHCl) nm (e) 327.0 (30,700); 422.5 (60,500); 692.0 
(10,100); 752.0 (36,400). 
Attempts at binding cadmium with ligand 2 were con 
ducted. Several milligrams of compound 2 were stirred 
with an excess of cadmium chloride in chloroform/methanol 
as per the direct insertion methods outlined above. Even 
after 2 days, however, UV/VIS (monitoring the Q-type band 
at 751), indicated that little or no metal insertion had taken 
place. Due to the difficulty of preparing compound or ligand 
2 and the obvious success of the direct insertion procedures 
described herein, no attempts were made to examine other 
metallation methods. 
The preparation of complex 3AOCl was as follows. The 
sp form of the ligand (1A)'' (40 mg, 0.08 mmol) was stirred 
with cadmium chloride (21.4 mg, 0.08 mmol) in chloroform/ 
methanol (150 ml, v/v2/1) for 1 day. The dark green reaction 
mixture was concentrated under reduced pressure on a rotary 
evaporator and chromatographed through silica gel using 
first pure chloroform and then chloroform/methanol (v/v 
191) as eluents. After discarding several leading red bands, 
the dark green band was collected and taken to dryness in 
vacuo to give compound 3 OCl. This material was recrys 
tallized from chloroform/n-hexane to give analytical pure 
compound 3ACl as a dark green powder in 24% yield. For 
3oCl: 'H-NMR (CDC1): 8=1.55-1.67 (12H, m, CHC 
H), 3.03 (6H, s, CH), 3.04-3.55 (8H, m, CHCH), 8.27 
(2H, m, phen. CH), 9.23 (2H, s, CH=N), 9.40 (2H, m, phen. 
CH), 11.30 (2H, s, CH-C); C NMR (CDC1): 8=9.8, 
17.3, 18.1, 19.1, 19.2, 117.6, 117.8, 128.4, 132.7, 138.2, 
139.3, 145.4, 146.7, 150.5, 153.5, 155.0; FAB MS (3-ni 
trobenzyl alcohol matrix, 8 keV acceleration): m/e 602 
(“Cd, M, 100), 601 (Cd, M, 64), 600 (?Cd, M., 84); 
IR (KBr) v=2950, 2910, 2855, 1635, 1605, 1380, 1255, 
1210, 1090, 1010, 795 cm; UV/VIS nm (e) 327.0 
(32,800); 424.0 (72,700); 704.5 (11,000); 767.5 (41,200); 
anal. calcd for CHNCdeClo(/30HO): C, 59.54; H, 
5.46; N, 10.85. Found: C, 59.78; H, 5.32; N, 10.80. 
The preparation of complex 3AoNO was as follows. The 
sp form of the ligand (1) (40 mg, 0.08 mmol) was stirred 
with cadmium nitrate tetrahydrate (31 mg, 0.1 mmol) in 
chloroform/methanol (150 ml, viv-/2) for 1 day. The dark 
green reaction mixture was then concentrated and purified 
by chromatography on silica gel as described above. The 
resulting crude material was then recrystallized from chlo 
roform/n-hexane to give analytical pure 3ONO in 27% 
yield. For 3oNO; H NMR (CDC1): 8=1.55-1.70 (12H, 
m, CHCH), 3.04 (6H, s, CH), 3.42-3.55 (8H, m, C 
HCH.), 8.27 (2H, m, phen. CH), 9.20 (2H, S, CH=N), 
9.30 (2H, m, Phen. CH), 11.07 (2H, s, CH=C); FAB MS 
(3-nitrobenzyl alcohol matrix, 8 KeV acceleration): m/e 602 
(“Cd, M, 100) 601 (Cd, M., 61) 600 (?Cd, M., 87): 
IR (KBr) v=2960, 2920, 2860, 1600, 1550, 1440, 1375, 
1200, 1130, 1075, 1040,975,930,900, 740 cm; UV/Vis 
2 nm (e)=328.0 (39,900), 425.0 (82,800), 706.0 (14,400), 
770 (49,800); Anal. calcd for CHNCdoNOO(4H2O): 
C, 57.19; H, 5.25; N, 12.50. Found: C, 57.12; H, 5.19; N, 
11.80. 
Attempts to demetallate complex 3AoNO were made. In 
an effort to obtain the free sp” bridged ligand 2A, the above 
complex in chloroform was stirred for several hours in the 
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presence of sodium sulfide and independently with sodium 
thiosulfate. No significant changes in optical properties were 
observed. Although this did not rule out the possibility that 
changes in axial ligation might be taking place, these obser 
vations provided reasonable evidence that little or no demet 
allation occurs under the reaction conditions. In the case of 
sodium sulfide, this critical conclusion was further sup 
ported by FAB MS: Other than the starting cationic complex 
3A, no evidence was obtained for any moderate to high 
molecular weight volatile products in the mass spectrum. 
When subject to treatment with aqueous acid, complex 
3ONO appears to undergo hydrolysis (at the imine resi 
dues) and hence demetallation. The rate of this process, 
however, is strongly pH dependent, the half-life being, for 
instance, on the order of several hours in the presence of ca. 
0.1N HC. 
Preparation and isolation of complex 4boNO. The sp 
form of the ligand (1A) (40 mg, 0.08 mmol) was stirred with 
cadmium nitrate tetrahydrate (31 mg, 0.1 mmol) in chloro 
form/methanol (150 ml, v/v=/2) for 1 day. The dark green 
reaction mixture was concentrated on a rotary evaporator 
and chromatographed through Sephadex using first neat 
chloroform and then chloroform/methanol (v/v 1%) as elu 
ents. After discarding several leading red bands, the dark 
green band was collected and concentrated to give a dark 
green solid. This was recrystallized from chloroform/n- 
hexane to give a mixture of crystalline and noncrystalline 
solids in 27% yield. For this bulk material: 'H-NMR 
(CDC): 8-1.55–1.72 (12H, m, CHCH). 3.04 (6H, s, 
CH), 3.45–3.58 (8H, m, CH,CH), 6.4 (ca. 34H, br, s, 
BzIm), 6.81 (ca. 5/5H, br. S., BzIm), 7.27 (ca. 54H, s, BzIm), 
829 (2H, m, phen. CH), 9.21 (2H, s, CH=N), 9.32 (2H, m, 
phen. CH), 11.08 (2H, s, CH=C); FAB MS (3-nitrobenzyl 
alcohol matrix, 8 keV acceleration): mile 602 ('Cd M", 
100) 601 (Cd, M., 67) 600 (Cd, M., 78); IR (KBr) 
v=2970, 2935, 2875, 1560, 1382, 1356, 1300, 1258, 1212, 
1085, 1050, 985,910, 755 cm; uv/vis W nm (e) 325.0 
(29,000); 425.0 (64.400); 710.5 (9,800): 767.5 (38,500); 
anal. Found: C, 42.42; H, 4.28; N, 10.34 (calcd for 
CHNCdoNOo(%HO): C, 57.19; H, 5.25; N, 12.50; 
calcd for CHNCdoNOoBzImoCHCla: C, 53.35; H, 
4.59; N, 12.44; calcd for CHNCdoNOOCHCl: C, 
41.26; H, 3.66; N, 8.25). The single crystal of 4b used for 
the X-ray structure determination was isolated from residual 
noncrystalline material following a second recrystallization 
which involved layering a concentrated solution of the 
above crude material in CDCl3 with n-hexane and letting 
stand for several months in the refrigerator. 
Preparation of complex 5aoNO. In a fashion similar to 
that used to prepare the crude cadmium-containing complex 
described above, the sp form of the ligand (1A) was treated 
with cadmium nitrate tetrahydrate and purified on Sephadex. 
To a ca. 0.7 ml, 0.005M sample of this product in CDCl, 
was added 25 Jul of pyr-Ds. The resulting solution was 
layered with n-hexane, and placed in the refrigerator. After 
several months, green crystals were isolated in nearly quan 
titative yield. The molecular composition of these crystals 
was determined, on the basis of the single crystal X-ray 
diffraction analysis reported earlier,' to be 5aoNOCHCl, 
H NMR (CDCl/pyr-D) 8=1.55-1.70 (12H, m, CHC 
H), 3.22 (3H, s, CH), 3.45-3.56 (8H, m, CHCH), 8.40 
(2H, m, phen. CH), 9.32 (2H, s, CH=N), 9.75 (2H, m, phen. 
CH), 11.62 (2H, s, CH=C); UV/VIS (CHC1-pyr v/v 194) 
nm (e) 321.5 (45,000), 426.5 (79,000), 700.5 (13,500), 
765.5 (51.900). 
The H NMR titration of 30NO, with BzIm or pyr-D 















80° C. under reduced pressure (1 mmHg) for 1 day. Starting 
samples for titration were then prepared by dissolving this 
five coordinate complex (3.32 mg, 0.005 mmol) in 0.7 to 
0.75 ml of CDCl and transferring quantitatively to an NMR 
tube. To such samples were then added increasing aliquots 
of either BzIm or pyr-D (as solutions of known concentra 
tion in CDCl3) and recording the chemical shift of the 
"meso" protons at 27 C. Control experiments were also 
carried out by adding known quantities of CFCOH, DO, 
and NHNQ to similar stock solutions of 3oNO. In these 
various "H NMR titrations the absolute chemical shifts for 
any given base to ligand ratio were found to vary by less than 
0.05 ppm between independent runs, with the values of 
8-8, the critical observable used for the K determinations 
(see below), being found to vary even less (generally 
s0.003 ppm). 
Determination of Binding Constants. Inspection of FIG. 
13 and FIG. 14 shows that the binding of BzIm to cation 3 
may be considered as two well-separated equilibrium pro 
cesses. The chemical shift data obtained for the "meso' 
signals as a function of added BzIm were thus analyzed as 
such at both very low and very high conversion: Standard 
Scatchard (single reciprocal) plots were constructed by 
plotting (8-6)/EBzIm) vs (8-6) according to equation 4 
(which corresponds to eq. 5.13 of ref.38), obtaining Kas the 
absolute value of the slope and the term (8-6)K as the 
intercept. 
Here 8 is the observed chemical shift, 8 is the initial 
chemical shift of the pure five or six coordinate starting 
complex (3AONO or 4b-NO), 8 the chemical shift 
calculated for the final mono- or bisligated complexes 
4boNO or 5aoNO, K the equilibrium constant in ques 
tion, and BzIm) the concentration of free, uncomplexed 
benzimidazole. In both the low and high conversion 
regimes, it proved necessary to correct for bound benzimi 
dazole so as to obtain valid expressions for BzIm) in terms 
of added benzimidazole (Bzim). This was done in a 
straightforward manner according to the expressions given 
in equations 5 and 6, where lig) represents the concentra 
tion of the starting five coordinate ligand 3 ONO. 
(Bzlm)=(Bzlm)-lig)(6-8)/8-6) at low Bzim), (5) 
BzImeBzIm)-lig) at high Bzim) (6) 
Using these corrected values for BzIm), straight line Scat 
chard plots were obtained with Rs 0.99 and 0.98 respec 
tively for the low and high BzIm), regimes giving values of 
K and K of 1.80x10M and 12.9M respectively. The 
value for K is considered to be quite reliable (estimated 
error s 15%); the low solubility of BzIm and the resulting 
incomplete nature of the titration associated with the for 
mation of 5aoNO, however, makes the value obtained for 
K. somewhat more approximate (estimated error s25%).' 
The changes in "meso' proton chemical shift as a function 
of added pyr shown in FIG. 15 indicate a clear absence of 
two distinct binding regimes. Moreover as expected, 
attempts to fit the data as a simple monoligation process (to 
give 6CN material) according to eq. 1 did not work. It 
therefore proved necessary to analyze the data in terms of 
two concurrent equilibrium processes. This was done using 
the convenient iterative procedure outlined by Connors. 
Here the equations of interest, corresponding to eqs. 4.31 
and 4.32 of Connors, as adopted for NMR analyses, are: 
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where 8 is the observed chemical shift, 8 is the initial 
chemical shift of the pure five coordinate starting complex 
3oNO, All is the total chemical shift difference correspond 
ing to the formation of the pure putative monoligated six 
coordinate species, A is the total chemical shift corre 
sponding to the formation of the bisligated cationic species 
5a from the initial five coordinate material, and pyr) is the 
free pyridine concentration. A precise expression for pyr is 
given by equation 9, where (pyr) is the concentration total 
added pyridine, and lig) represents the concentration of the 
starting five coordinate ligand 3ONO 
KK, pyr') (9) 
Inspection of the binding isotherm (FIG. 16), however, 
suggested that the approximation pyrspyr would be 
reasonably valid over much of the titration range. Initial 
iterative solutions of eqs. 7 (plotting 1/pyr-KA/(8–6) 
vs. pyr-A/8-6)-1}, giving KK2 and -K as the slope 
and intercept respectively) and 8 (plotting (8-6) {1+K 
(pyr)+KK2pyr'}/(pyr) vs. (pyr), giving K.K.A. and 
KA as the slope and intercept respectively) were therefore 
made using this greatly simplifying assumption. They con 
verged quickly to give initial, uncorrected values of 
K=1.5M and KK=308M'. These values confirmed that 
under the conditions of the experiment (where 3oNO= 
0.005M), the approximation pyre pyr) is valid to within 
s4% in the regime of greatest interest, namely 3<pyridine) 
/ligandk10 and 0.005M in 3DMO. When corrections are 
made for this small percentage, final values of K of 
s1.6M and KK=315M’ are obtained. We consider it 
important to stress that although the value of KK is well 
determined (estimated errors 10%), the nature of the data 
does not allow K (and hence K) to be defined with 
precision (estimated errors.50%). This uncertainty, however, 
does not detract from the central conclusions described 
herein. 
X-ray Experimental for complex 4b. For 
4beNOOCHCl: CHNOClCd, M=900.57. The data 
crystal was a very dark green plate of dimensions 0.06X 
0.22x0.44 mm, which was grown by slow diffusion from 
CHCl-hexanes and separated from the accompanying non 
crystalline material as described above. The data were 
collected on a Nicolet R3 diffractometer, with a graphite 
monochromator, using Mo Ko, radiation (A=0.71069 A) and 
a Nicolet LT-2 low-temperature delivery system (163 K.). 
Lattice parameters were obtained from least-squares refine 
ment of 26 reflections with 19.2°<20<24.4. The space 
group was triclinic, P1 (No. 2), with Z=2, F(000) =920, 
a=11.276(4), b=12.845(3), c=14913(4) A, o=84.82(2), 
B=69.57(2), -85.84(2), v=2014(1) A, p=1.48 g-cm. 
Data were collected using the omega scan technique (7191 
reflections, 6566 unique, R=0.064), 20 range 4.0°-50.0, 
1.2 () scan at 3-6/min. (h=0->14, k=-15, 1=-18->18). 
Four reflections (-2.2,0;3,2,3; 2-3-1, -10,-4) were 
remeasured every 146 reflections to monitor instrument and 
crystal stability. Decay correction range on I was 0.9863–1, 
076. Data also corrected for L effects and absorption (based 
on crystal shape; transmission factor range 0.8533-0.9557, 
=7.867 cm). Reflections having F-60 (F) considered 
unobserved (3272 reflections). The structure was solved by 
heavy atom and Fourier methods and refined by full-matrix 
least-squares procedures in blocks of 253 and 287 with 
anisotropic thermal parameters for the non-H atoms (except 
03A of the disordered NO-group and the terminal C 














C29 site occupancy factor 0.44(2)), C29A, C31 site occu 
pancy factor 0.37(2) and C31A). Nitrate disordered about 
two orientations of the N atom (N1B) with site occupancy 
factors for the minor orientation (O atoms labeled with A) of 
0.45(2). H atoms were calculated and refined with isotropic 
thermal parameters riding on the relevant C atom. CHCL 
solventis disordered by rotation about a C-Cl bonding axis 
(CIC-C11) with site occupancy factor for the minor com 
ponent (Cl atoms labelled with A) of 0.43(2). Due to the 
disorder, the chloroform H atom position was not calculated. 
X w(IF-IFI)’ minimized, where w=1/(o(F))’+0.0118(F) 
ando(F)=0.5kI(o(I)). Intensity, I, given by (peak back 
ground)X(scan rate) and k is the correction due to Lp effects, 
absorption and decay. Sigma(I) estimated from counting 
statistics; o(I)="peak" background)'x(scan rate)). Final 
R=0.0781 for 3294 reflections, wR=0.114 (RF-0.143, 
wR-0.176) and a goodness of fit=1.00. Maximum 
Afolk0.1 in the final refinement cycle and the minimum and 
maximum peaks in the final AF map were -0.97 and 1.69 
e-/A, respectively (in the region of the Cd atom). Data. 
reduction, structure solution and initial refinement were 
accomplished using Nicolet's SHELXTL-PLUS software 
package. The final refinement was done using SHELX76. 
Neutral atom scattering factors for the non-H atoms from 
Cromer and Mann, with anomalous-dispersion corrections 
from Cromer and Liberman, while scattering factors for 
the H atoms from Stewart, Davidson and Simpson; linear 
absorption coefficient from the International Tables for 
X-ray Crystallography (1974). The least-squares planes 
program was supplied by Cordes; other computer pro 
grams from reference 11 of Gadol and Davis." 
Table 1 shows sectional coordinate or equivalent isotropic 
thermal parameters (A) for non-hydrogen atoms of 
4boCHCls. Table 2 shows bond lengths (A) and angles () 
for non-hydrogen atoms of cation 4b. TABLE 1. Fractional 
coordinates and isotropic or equivalent isotropic' thermal 
parameters (A) for non-hydrogen atoms of 
4boNOOCHCl, 
Aton X y Z U 
C .37392(8) .12411(6) 04542(7) .0573(4) 
N1 5259(9) 1813(7) .1140(9) 065(5) 
C2 5321 (13) 1503(10) 2032(11) 062(6) 
C3 6213(12) 2115(11) .2219(10) 064(6) 
C4 6661 (11) .2783(9) .1439(11) 061(6) 
C5 6066(12) 2575(9) .0765(11) 060(6) 
C6 .6340(12) 3124(9) -0106(12) 065(7) 
C7 5828(11 .3039(8) -0848(11) .063(6) 
N8 4929(9) 2314(7) -0754(8) .056(4) 
C9 4750(12) 2437(10) -1581 (11) 070(6) 
C10 .5492(14) 3233(11) -.2225(10) 075(6) 
C1 .6178(12) 3604(9) -1782(11) 069(6) 
C12 3827(14) 1784(12) -1763(10) 073(6) 
N13 .3236(10) 1169(8) -1068(8) 057(4) 
C14 .2359(11) .0438(11) -1074(10) .063(6) 
C15 1851 (13) 0468(12) -1834(10) .072(6) 
C16 1028(14) -0250(12) -.1825(10) 067(6) 
C17 0648(13) -0982(12) -.1067(11) 071(7) 
C18 .1077(12) -.1040(9) -0331 (11) .074(7) 
C19 1952(12) -0304(8) -0304(11) .064(6) 
N2O 2428(10) -0258(9) 042009) .065(5) 
C2 .2112(13) -0873(9) 1201(11) .065(6) 
C22 .2643(12) -0711(9) 1918(11) 065(7) 
N23 .3510(10) 0013(6) 1716(9) .061(5) 
C24 .3782(14) .0029(10) .2535(13) 076(7) 
C25 .3076(14) -0727(10) 3260(12) 08007) 
C26 .2349(15) -1183(9) .2854(11) 073(7) 
C27 4669(13) 0715(10) 2649(11) 067(6) 
C28 .6508(14) 2018(13) 3139(11) 084(7) 
C29 553(5) .234(4) 400(3) 105(15) 
C29A .590(3) .28202) 381(2) 082(8) 
Atom 
"For anisotropic atoms, the U value is U calculated as U = % XXU, 








































5579(11) - 1933(13) 
3512(14) -3236(10) 













.2261 (8) .5862(6) 












Bond Lengths (A) and Angles () for non-H atoms 


































1. 2 3 1-2 1-2-3 
C2 N1 C5 1.38(2) 107.2(13) 
C5 N1 1.33(2) 
C3 C2 C27 1.43(2) 124.(2) 
C3 C2 N1 109.5(11) 
C27 C2 N1 1.37(2) 126.3(15) 
C4 C3 C28 1.35(2) 129.3(14) 
C4 C3 C2 105.9(14) 
C28 C3 C2 1.51(2) 124.7(12) 
C5 C4 C30 1.44(3) 126.9(13) 
C5 C4 C3 107.8(12) 
C30 C4 C3 1.55(2) 125.(2) 
C6 C5 N 1.37(2) 129.(2) 
C6 C5 C4 121.7(12) 
N1 C5 C4 109.5(13) 
C7 C6 C5 1.43(3) 129.2(12) 
N8 C7 C11 1.39(2) 110.7(14) 
N8 C7 C6 121.3(12) 
C1 C7 C6 1.45(2) 127.8(12) 
C9 N8 C7 1.31 (2) 103.3(11) 
C10 C9 C12 1.43(2) 127.(2) 
C10 C9 N8 113.6(14) 
Cl2 C9 N8 1.49(2) 119.7(11) 
C11 C10 C34 1.32(2) 127.8(13) 
C11 C10 C9 106.7(14) 
C34 C10 C9 1.51(2) 125.(2) 
C32 C1 C7 1.52(2) 125.(2) 
C32 C11 C10 129.1 (15) 
C7 C11 C10 105.7(11) 
N13 C12 C9 1.26(2) 115.2(15) 
C14 N13 C12 1.4.1(2) 126.1 (14) 
C15 C14 C19 1.43(2) 119.5(13) 
C15 C14 N13 121.7(12) 
C19 C14 N13 1.39(2) 118.7(14) 
C16 C15 C14 1.25(2) 120.2(13) 















Bond Lengths (A) and Angles () for non-H atoms 
of cation 4ba. 
1 2 3 1-2 1-2-3 
C18 C17 C16 1.34(3) 123.(2) 
C19 C18 C17 1.43(2) 120,0(13) 
N20 C19 C14 1.37(2) 116.6(12) 
N20 C19 C8 125.7(12) 
Cl4 C19 C18 118.(2) 
C21 N20 C19 1.30(2) 124.2(13 
C22 C21 N2O 1.43(3) 118.3(13) 
N23 C22 C26 1.34(2) 113.(2) 
N23 C22 C21 118.0(13) 
C26 C22 C21 1.41(2) 129.1(12) 
C24 N23 C22 1.36(2) 104.7(12) 
C25 C24 C27 1.44(2) 125.(2) 
C25 C24 N23 111.1 (14) 
C27 C24 N23 1.44(2) 123.9(12) 
C26 C25 C36 1.37(3) 127.9(13) 
C26 C25 C24 105.(2) 
C36 C25 C24 1.52(3) 127.(2) 
C35 C26 C22 1.54(2) 124.(2) 
C35 C26 C25 129.(2) 
C22 C26 C25 106.3(12) 
C2 C27 C24 130.(2) 
C29 C28 C3 1.44(4) 118.(3) 
C29A C28 C3 1.46(3) 115.(2) 
C31A C30 C4 1.51(3) 112.(2) 
C31 C30 C4 1.57(3) 111.(2) 
C33 C32 C11 1.54(2) 114.0(11) 
C37 C36 C25 1.47(2) 114.(2) 
C9A NA C2A 1.40(2) 108.5(10) 
C2A N1A 1.40(2) 
N3A C2A N1A 1.35(2) 107.(2) 
C4A N3A C2A 1.31(3) 109.4(14) 
C5A C4A C9A 1.47(3) 115.(2) 
C5A C4A N3A 133.3(14) 
C9A C4A N3A 1.40(2) 111.2(13) 
C6A C5A C4A 1.34(3) 120.(2) 
C7A C6A C5A 1,47(3) 124.(2) 
C8A C7A C6A 1.37(2) 115.(2) 
C9A C8A CA 1.38(2) 121.7(14) 
N1A C9A C4A 103.7(12) 
N1A C9A C8A 132.1(11) 
C4A C9A C8A 124.1 (13) 
The characterization by X-ray diffraction analysis of a six 
coordinate pentagonal pyramidal cadmium(II) cationic com 
plex 4b derived from a novel aromatic 22 at-electron 
pentadentate "expanded porphyrin” ligand (2A) is described. 
The X-ray structure reveals the five central donor atoms of 
the macrocycle to be coordinated to the cadmium(II) cation 
which in turn lies 0.334(2) A above the mean plane of the 
macrocyle and is further ligated by an apical benzimidazole 
ligand. As is true in the corresponding pentagonal bipyra 
midal bispyridine adduct 5a, the X-ray structure of cation 
4ba indicates the macrocyclic ligand to be nearly planar 
(maximum deviation 0.154(13) A for C15) with the five 
donor nitrogen atoms defining a near circular cavity with a 
center-to-nitrogen radius of s2.42 A. The crystals of 
4bAONO used for the X-ray diffraction analysis were iso 
lated from an inhomogeneous mixture of crystalline and 
noncrystalline material obtained following treatment of the 
sp form of the ligand (1a) with CdCNO)o(H2O), and 
subsequent purification on sephadex. The proton NMR 
spectrum in CDCl of this bulk material is essentially 
identical to that of the pure five coordinate complex 3A 
prepared independently, but showed the presence of a broad 
feature at ca. 6.4 ppm and two sharper peaks at 6.81 and 7.27 
ppm ascribable to the bound benzimidazole ligand. These 
diagnostic ligand features are reproduced upon titrating the 
pure five coordinate complex 3 with roughly 3% equivalent 
of benzimidazole. This finding suggests that the bulk mate 
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rial from which crystals of 4b AoNO were isolated consists 
of a mixture of crystalline and noncrystalline six and five 
coordinate species and supports the hypothesis that the 
bound benzimidazole found in cation 4ba is derived from 
degradative side reactions associated with the metal inser- 5 
tion and accompanying ligand oxidation. From these titra 
tions the values for the sequential formation constants (K 
and K) for the binding of the first and second equivalents 
of benzimidazole to the five coordinate cationic complex 3 
were determined to be 1.8x10M respectively. For the 10 
complexation of pyridine to 3ONO, KOK values of 
1.6M and 315M respectively were determined from 
similar H NMR titrations. These results indicate that in 
benzimidazole-containing chloroform solutions an extended 
concentration range exists wherein the pentagonal pyrami- 15 
dal complex 4ba is the primary cadmium containing species, 
whereas in the presence of pyridine it is either the unligated 
complex 3A or the coordinatively saturated pentagonal bipy 
ramidal species 5a, which will dominate in solution. 
Published literature references in the following list are 20 
incorporated by reference herein for the reasons cited. 
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EXAMPLE 3 
Gadolinium(III) complexes derived from strongly binding 
anionic ligands, such as diethylenetriamine pentaacetic acid 
(DTPA), ''1,4,7,10-tetraazacyclododecane N,N',N."N"- 
tetraacetic acid (DOTA),' and 1,10-diaza-4,7,13,16-tet 
raoxacyclooctadecane-N,N'-diacetic acid (dacda),' are 
among the most promising of the paramagnetic contrast 
currently being developed for use in magnetic resonance 
imaging (MRI). Indeed, (Gd-DTPA) is now undergoing 
clinical trials in the United States for possible use in 
enhanced tumor detection protocols.' Nonetheless, the syn 
thesis of other gadolinium(III) complexes remains of interest 
since such systems might have greater kinetic stability, 
superior relaxivity, or better biodistribution properties than 
the existing carboxylate-based contrast agents. One 
approach currently being pursued is based on using water 
soluble porphyrin derivatives, such as tetrakis(4-sul 
fonatophenyl)porphyrin (TPPS).' Unfortunately, the 
large gadolinium(III) cation cannot be accommodated com 
pletely' within the relatively small prophyrin binding core 
(r=2.0 A'), and, as a consequence, gadolinium porphyrin 
complexes are invariably hydrolytically unstable.''' 
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Larger porphyrin-like ligands, however, might offer a means 
of circumventing this problem.''' 
As previously described, the present invention involves' 
the synthesis of a novel "expanded porphyrin” system, 1 (to 
which the trivial name "texaphyrin” has been assigned), 
and the structure of the bispyridine adduct of its cad 
mium(II) complex 2. See FIG. 17A and FIG. 17B for the 
structures of compound or complex 1-11. The presence in 
this structure of a near circular pentadentate binding core 
which is roughly 20% larger than that of the porphyrins.' 
coupled with the realization that almost identical ionic radii 
pertain for hexacoordinate Cd" (r=0.92 A) and Gd 
(r=0.94 A),' prompted exploration of the generallanthanide 
binding properties of this new monoanionic porphyrin-like 
ligand. The synthesis and characterization of a water-stable 
gadolinium(III) complex (7) derived formally from a new 
16,17-dimethyl substituted analogue (6) of the original 
"expanded porphyrin' system, as well as the preparation and 
characterization of the corresponding europium(III) and 
samarium(III) complexes 8 and 9 (See FIG. 17B). 
Electronic spectra were recorded on a Beckman DU-7 
spectrophotometer. IR spectra were recorded, as KBrpellets, 
from 4000 cm to 600 cm on a Perkin-Elmer 1320 
spectrometer. Low resolution fast atom bombardment mass 
spectrometry (FAB MS) was performed at Austin using a 
Finnigan-MATTSQ-70 instrument and either 3-nitrobenzyl 
alcohol or glycerol/oxalic acid as the matrix; high resolution 
FABMS analyses (HRMS) were performed at the Midwest 
Center for Mass Spectrometry using CsI as a standard. 
Elementary analyses were performed by Galbraith Labora 
toes. 
Materials. All solvents and reagents were of reagent grade 
quality, purchased commercially, and used without further 
purification. Sigma lipophilic SEPHADEX (LH-20-100) 
and Merck type 60 (230-400 mesh) silica gel were used for 
column chromatography. 
Preparation of Nd complex 3. The sp form of the ligand 
10' (50 mg, 0.1 mmol) was stirred with neodymium nitrate 
pentahydrate (63 mg, 0.15 mmol) and proton sponge (64 mg, 
0.3 mmol) in chloroform/methanol (150 ml, w/v /2) for one 
day. The dark green reaction mixture was poured onto 
ice/water/ammonium chloride and extracted with chloro 
form. The organic layer was washed with aqueous ammo 
nium chloride and concentrated under reduced pressure. The 
complex was chromatographed through sephadex using neat 
chloroform, chloroform/methanol (10:1), methanol, and 
water. The dark green band collected from methanol was 
concentrated and recrystallized from chloroform/methanol/ 
n-hexane (ratio of chloroform to methanol is 1 to 2) to yield 
13 mg of 3 (18%) For 3: UV/VIS (CHOH) *, (e): 330.5 
(33,096), 432.5 (85,762), 710.5 (10,724), 774.5 (38.668); 
FAB MS (glycerol matrix); me (relative intensity) 631 
('Nd,95), 633 ('Nd, 100), 635 ('Nd, 77); IR (KBr) * 
3360, 2965, 2930, 2870, 1610, 1560, 1450, 1400, 1350, 
1250, 1205, 1135, 1080, 1050, 980, 940, 905, 755 cm. 
The preparation of Sm complex 4 was as follows. The 
macrocyle 10 (40 mg, 0.08 mmol) was stirred with 
platinum oxide (18 mg. 0.08 mmol) and samarium acetate 
hydrate (69 mg, 0.2 mmol) under reflux in benzene/metha 
nol (50 ml, viv, /1). After two hours the reaction mixture was 
filtered through celite and concentrated under reduced pres 
sure. The concentrate was purified by chromatography 
through Sephadex using only chloroform as an eluent. After 
discarding a red band, a green band was collected, concen 
trated in vacuo, and recrystallized from chloroform/n-hex 
ane to give 0.8 mg of 4 (ca. 1%). For: UV/VIS *nm 














m/e (relative intensity). 635 (''Sm, 78), 636 (''Sm, 72), 
637 (''Sm, 73), 640 ('Sm 100), 642 ('Sm, 55). 
The preparation of Eu complex 5 was as follows. The 
macrocycle 10' (50 mg, 0.1 mmol) was stirred with 
europium acetate hydrate (34 mg, 0.1 mmol) and proton 
sponge (64 mg., 0.3 mmol) in chloroform/methanol (150 ml, 
v/v, /2) for one day. The reaction mixture was poured onto 
ice/water and extracted with chloroform. The organic layer 
was washed with aqueous ammonium chloride then concen 
trated and recrystallized from chloroform/n-hexane. The 
recrystallized solid was purified by column chromatography 
through Sephadex using neat chloroform and neat methanol 
as eluents. The dark green band collected in methanol was 
concentrated to yield a small amount of a dark green solid 
(<1%). For 5: UV/VIS *, nm 438, 700, 765; FAB MS 
(3-nitrobenzyl alcohol matrix): m/e (relative intensity) 639 
(Eu, 94), 641 (Eu, 100). 4,59,24-Tetraethyl-10,16,17, 
23-tetramethyl-13,20,25,26,27-pentaazapentacyclo 
(20.2.1.1.1.0'']heptacosa-3,5,8,10,12,14(19), 
15, 17.20,22,24-undecene (11). This macrocycle was pre 
pared in ca. 90% yield from 1,2-diamino-3,4-dimethylben 
Zene and 2,5-bis-(3-ethyl-5-formyl-4-methylpyrrol-2-ylm 
ethyl)-3,4-diethylpyrrole using the acid catalyzed procedure 
reported earlier for the preparation of 10.” For 11: mp 200 
C dec; H NMR B1.06 (6 H, t, CH,CH), 1.13 (6 H, t, 
CHCH-) 2.15 (6H, s, phenyl-CH), 2.22 (6H, s, pyrrole-C 
H), 2.38 (4H, q, CHCH), 2.50 (4H, q, CHCH), 3.96 (4 
H, s, pyrrole-CH2), 7.19 (2 H, s, aromatic), 8.10 (2 H, s, 
CHN), 11.12 (1H, s, NH), 12.48 (2 H, s, NH); C NMR 
89.49, 15.33, 16.47, 17.22, 17.71, 19.52, 22.41, 117.84, 
120.40, 120.75, 125.11, 125.57, 134.95, 135.91, 141.63; 
UV/VIS *, 367 mm; FAB MS, M 522; HRMS, 
M'521.35045 (calc. for CHN 521.35185). 
Preparation of Gd complex 7. The sp form of ligand 11 
(42 mg, 0.08 mmol) was stirred with gadolinium acetate 
tetrahydrate (122 mg, 0.3 mmol) and proton sponge (54 mg, 
0.25 mmol) in chloroform/methanol (150 ml, w/v. 4) for one 
day. The dark green reaction mixture was concentrated 
under reduced pressure and chromatographed through silica 
gel (25 cm.X1.5 cm.) which was pretreated with chloroform/ 
triethylamine (50 ml, v/v 2%). Chloroform/triethylamine 
(2%) and chloroform/methanol/triethylamine 25/2.5/1 v/v) 
was used as eluents. A dark red band was first collected 
followed by two green bands. The last green band, which 
showed a clear aromatic pattern by UV/VIS, was concen 
trated and recrystallized from chloroform/n-hexane to give 
14 mg (22%) of the Gd complex 7. For 7: FAB MS 
(methanol/oxalic acid/glycerol matrix); m/e (relative inten 
sity) 671 (Gd,58), 672 (5Gd, 78), 673 (57Gd, 94), 674 
(Gd, 100), 676 (Gd, 64); HRMS, M674.2366 (calc for 
CHN'Gd 674.2368): UV/VIS (CHCl) *, nm (e) 
339.5 (14,850), 450.5 (36.350), 694.5 (6,757), 758.0 (23, 
767); IR (KBr) * 2990, 2960,2900, 2830, 2765, 2700, 2620, 
2515, 1710, 1550, 1440, 1410, 1395, 1365, 1265, 1220, 
1180, 1150, 1105, 1090, 1060, 1040, 1095, 1045, 1015, 680 
cm; Anal. calc. for CHNGd(OH)2H2O: C, 54.89; 
H, 5.96; N, 9.41. Found: C, 54.49; H, 5.95; N, 8.97. 
The preparation of Eu complex 8 was carried out. The 
macrocycle 11 (53 mg, 0.1 mmol) was stirred with 
europium acetate hydrate (105 mg, 0.3 mmol) and proton 
sponge (64 mg, 0.3 mmol) in chloroform/methanol (150 ml, 
v/v /2) for 6 hrs. The dark green reaction mixture was 
concentrated under reduced pressure as described above 
with one exception. Chloroform/triethylamine (25:1) and 
chloroform/methanol/triethylamine (25:5:1) were used as 
eluents. The green complex 8 was recrystallized from chlo 
roform/n-hexane to yield 26 mg of product (33%). For 8: 
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UV/VIS (CHCl) *, nm (e) 339.5 (24,570), 450.5 (63, 
913), 696.0 (10,527), 759.0 (40,907); FAB MS (methanol/ 
oxalic acid/glycerol matrix): m/e (relative intensity) 667 
(Eu, 79), 669 (Eu, 100); HRMS, M., 669.2336 (calc 
for C.H. N5'Eu 669.2340); IR (KBr) * 2970, 2930, 
2870, 2740, 2680, 2600, 2500, 1700, 1535, 1430, 1350, 
1255, 1205, 1165, 1135, 1095, 1075, 1050, 1030, 980, 900 
cm; Anal. calc. for CHNEu(OH)O: C, 56.66; H, 
5.87; N, 9.72. Found: C, 55.92; H, 5.47; N, 9.95. 
The preparation of the Sm" complex 9s was as follows. 
The sp form of the ligand (11) (52 mg, 0.1 mmol) was 
stirred with samarium acetate hydrate (103.5 mg, 0.3 mmol) 
and proton sponge (64 mg., 0.3 mmol) in chloroform/ 
methanol (150 ml, v/v /2) for one day. The dark green 
reaction mixture was concentrated and purified by silica gel 
chromatography as described above. The resulting crude 
material was then recrystallized from chloroform/n-hexane 
to give 29 mg of 9 in 37% yield. For 9: UV/VIS (CHCl) 
*, nm (e) 339.5 (21,617), 451.0 (56.350), 695.5 (9,393), 
760.0 (35,360); FAB MS (3-nitrobenzyl alcohol): m/e (rela 
tive intensity) 663 (''Sm, 74.8), 664 (''Sm, 82.3) 665 
('Sm, 84.58), 668 (5°Sm, 100, 670 (5'Sm, 78.5); HRMS, 
M', 668.2300 (calc. for CH,N'Sm 668.2322); IR 
(KBr) * 2990, 2950, 2890, 2760, 2700, 2620, 2520, 1720, 
1620, 1550, 1440, 1360, 1265, 1215, 1175, 1145, 1105, 
1085, 1060, 995, 945, 910, 680 cm; Anal. calc for 
CHNSm(OH)O: C, 54.08; H, 6.14; N, 9.27. Found: 
C, 54.30; H, 5.66; N, 9.06. 
As described earlier,' (see Example 1) treatment of the 
methylene-bridged, or sp form of the texaphyrin macro 
cycle 10, with CdCII) salts in air saturated methanol/chlo 
roform at ambient temperature leads to the formation of the 
green CdCII) complex 2 in roughly 25% yield, with both 
metal insertion and oxidation taking place concurrently 
under the reaction conditions. When a similar procedure was 
carried out using a variety of trivalent lanthanide salts i.e. 
Ce(OTf), Pr(OAc), Nd(NO), Sm(OAc), Eu(OAc), 
Gd(OAc), DY(OTf), TbCl, Er(OTf), Tm(NO), and 
Yb(NO), no metal complexes of 1 (or 10) were obtained 
(as judged by the absence of changes in the UV/visible 
spectrum) If, however, N,N',N',N"-tetramethyl-1,8-diami 
nonaphthalene ("proton sponge') was added to the various 
reaction mixtures, the high energy, low intensity band of 10 
at *=365 nm disappeared over the course of several hours 
to several days (depending on the salt in question) and was 
replaced by two strong transitions in the 435–455 nm (Soret) 
and 760-800 nm (Q band) regions, suggesting that ligand 
oxidation and metal binding had occurred.” Unfortunately, 
isolation of these putative metal-containing products proved 
problematic: Direct chromatography on either silica gel or 
lipophilic Sephadex in general gave only small quantities of 
metal-free oxidized ligand 1 and essentially none of the 
desired metalated material. Indeed, only in the case of the 
samarium(III) acetate salt did it prove possible to isolate a 
trace quantity (ca. 1% yield) of the desired complexes (4) by 
chromatography on Sephadex. It was interesting to find, 
however, that a dark green neodymium(III) complex 3 
could be obtained in almost 20% yield by quenching the 
reaction mixture with ice water, extracting repeatedly with 
chloroform, washing with aqueous ammonium chloride, 
purifying by chromatography on Sephadex, and recrystal 
lizing from chloroform/methanol/n-hexane. Unfortunately 
this work-up procedure proved ineffective in the case of the 
other putative lanthanide complexes (including, unfortu 
nately, that derived from Gd3+), although it did prove 
possible to obtain trace quantities of the europium(III) 













Since spectral evidence suggested that metal uptake and 
ligand oxidation were occurring when the sp macrocycle 
10, was treated with numerous other Ln salts, it was 
puzzling that only the neodymium(III) complex (3) could be 
isolated in reasonable yield. A careful analysis Suggested 
that, in certain instances, notably Sm", Eu", Gd, the 
problem was not due to hydrolytic instability. Rather, it 
derived from the very high water solubility of the lanthanide 
complexes which precluded reextraction back into organic 
solvents following the initial aqueous washes! This obser 
vational hypothesis led to the consideration that more hydro 
phobic texaphyrin analogues would prove valuable in the 
preparation and isolation of "expanded porphyrin” lan 
thanide complexes. 
To test the above assumption, a simple dimethylated 
analogue (11) of the original sphybridized ligand 10 was 
prepared. This new, more hydrophobic, sp hybridized 
ligand was obtained in ca. 90% yield by condensing 1,2- 
diamino-4,5-dimethylbenzene with 2,5-Bis-(3-ethyl-5- 
formyl-4-methylpyrrol-2-ylmethyl)-3,4-diethylpyrrole 
under acid catalyzed conditions identical to those used to 
prepare 10.” Treatment of this texaphyrin precursor with 
Gd(OAc), Eu(OAc), and Sm(OAc) under reaction and 
work up conditions similar to those used to obtain 3, then 
gave the cationic complexes 7, 8, and 9, as their dihy 
droxide adducts,' in 22%, 33%, and 37% yields respec 
tively. It appears that these increased yields derive directly 
from the increased hydrophobicity of the new dimethyl 
substituted texaphyrin ligand system (6). 
The new lanthanide complexes reported here are unique 
in several ways. For instance, as judged by fast atom 
bombardment mass spectrometric (FABMS) analysis, com 
plexes 3-5 and 7-9 are mononuclear 1:1 species, a 
conclusion that is further supported, in the case of com 
pounds 7-9, by both high resolution FAB MS accurate 
molecular weight determinations and combustion analysis. 
In other words, we have found no evidence of 1:2 metal to 
ligand "sandwich' systems, or higher order combinations as 
are often found in the case of the better studied lanthanide 
porphyrins.' 
The electronic spectra represents a second remarkable 
feature of these new materials: All six lanthanide complexes 
isolated to date display a dominant Soret-like transition in 
the 435-455 nm region which is considerably less intense 
than that observed in the corresponding metalloporphyrins 
(c.f. FIG. 18A and FIG. 18B)," and show a prominent low 
energy Q-type band in the 760–800 nm region. This latter 
feature is diagnostic of this class of 22 at-electron "expanded 
porphyrins' and is both considerably more intense and 
substantially red-shifted (by ca. 200 nm) as compared to the 
corresponding transitions in suitable reference lanthanide 
prophyrins (e.g., GdTPPS), *=575 nm'). Within the 
context of these general observations, it is interesting to note 
that complexes derived from the somewhat more electron 
rich ligand 6 all display Q-type bands that are blue shifted 
by ca. 5-15 nm as compared to those obtained from the 
original texaphyrin 1. 
A third notable property of complexes 7-9 is their high 
solubility in both chloroform and methanol. The fact that 
these three complexes are also moderately soluble (to 
roughly 10M concentrations) in 1:1 (v.v.) methanol/water 
mixtures was of particular interest. Moreover, as initially 
suggested on the basis of the preliminary studies with 3-5 
discussed above, these materials are stable to these solvent 
conditions. For instance, a 3.5x10M solution of the gado 
linium complex. 7 in 1:1 (v.v.) methanol/water at ambient 
temperature shows less than 10% bleaching of the Soret and 
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Q-type bands when monitored spectroscopically over the 
course of 2 weeks. This suggests that the half-life for 
decomplexation and/or decomposition of this complex is 
2100 days under these conditions. Under the conditions of 
the experiment described above, no detectable shifts in the 
position of the Q-type band are observed yet the Q-type 
transition of the free-base 6 falls ca. 20 nm to the blue of 
that of 7,' while shifts in this direction would be expected 
if simple demetalation were the dominant pathway leading 
to the small quantity of observed spectral bleaching. 
The strong hydrolytic stability of complexes 7-9 is in 
marked contrast to that observed for simple, water soluble 
gadolinium porphyrins, such as GdTPPS", which undergo 
water-induced demetalation in the course of several days 
when exposed to an aqueous environment." It thus appears 
likely that gadolinium(III) complexes derived from the new 
texaphyrin ligand 6, or its analogues, should provide the 
basis for developing new paramagnetic contrast reagents for 
use in MRI applications. In addition, the ease of preparation 
and stable mononuclear nature of complexes 7-9 suggests 
that such expanded porphyrin ligands might provide the 
basis for extending further the relatively underdeveloped 
coordination chemistry of the lanthanides. 
Literature citations in the following list are incorporated 
by reference herein for the reasons cited. 
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The photophysical properties of a new series of tripyr 
roledimethine-derived "expanded porphyrins” ("texaphy 
rins") are reported; these compounds show strong low 
energy optical absorptions in the 730-770 nm spectral range 
as well as a high triplet quantum yield, and act as efficient 
photosensitizers for the production of singlet oxygen in 
methanol solution. 
Photodynamic therapy is among the more promising of 
modalities currently being considered for the treatment of 
localized neoplasia and eradication of viral contaminants in 
blood.” As a result, considerable effort has been devoted to 
the development of effective photochemotherapeutic 
agents. To date, porphyrins and their derivatives, phthalo 
cyanines, and naphthalocyanines have been among the most 
widely studied compounds in this regard. Unfortunately, all 
of these dyes suffer from critical disadvantages. While 
porphyrin derivatives have high triplet yields and long triplet 
lifetimes (and consequently transfer excitation energy effi 
ciently to triplet oxygen),' their absorption in the Q-band 
region often parallels that of heme-containing tissues. Phtha 
locyanines and naphthalocyanines absorb in a more conve 
nient spectral range but have significantly lower triplet 
yields; moreover, they tend to be quite insoluble in polar 
protic solvents, and are difficult to funtionalize. Thus at 
present the development of more effective photochemo 
therapeutic agents appears to require the synthesis of com 
pounds which absorb in the spectral region where living 
tissues are relatively transparent (i.e., 700-1000 nm), have 
high triplet quantum yields, and are minimally toxic. The 
present inventors have recently reported (see Example 1) 
the synthesis of a new class of aromatic prophyrin-like 
macrocycles, the tripyrroledimethine-derived"texaphyrins', 
which absorb strongly in the tissue-transparent 730-770 nm 
range. The photophysical properties of metallotexaphyrins 
1-7 parallel those of the corresponding metallaporphyrins 
and the diamagnetic complexes 1-4 sensitize the produc 
tion of 'O, in high quantum yield. FIG. 19 shows the 
schematic structure, metal complexes and derivatives of 
compounds of the present invention (1-7). 
The absorption spectrum of 1°Cl is shown in FIG. 20A. 
This spectrum, which is representative of this class of 
compounds (cf. Table 3), is characterized by strong Soret 
and Q-type bands, the latter being of particular interest. The 
fluorescence excitation spectrum of this complex, monitored 
at the emission maximum (ca. 780 nm; see inset to FIG. 
20A), and the absorption spectrum are superimposable in the 
visible region (370-800 nm) showing that internal conver 
sion to the first excited singlet state is quantitative upon 











fluorescence quantum yields (b) for 1-4 are only 0–1%, 
the quantum yields for triplet formation (()) of these dia 
magnetic metalltexaphrins can approach unity and resemble 
those found for metalloporphyrins." The triplet-triplet tran 
sient spectrum of 1°Cl, given in FIG. 21, shows bleaching 
in the Soret- and Q-bands of the ground state and a positive 
absorbance change in the 450-600 nm region, again remi 
niscent of metalloporphyrin triplet spectra." The inset of 
FIG. 21A shows the decay of this triplet state in deoxygen 
ated methanol, from which a lifetime (t) of 67 is is 
calculated. Similar triplet spectra, lifetimes, and quantum 
yields were found for other diamagnetic metallotexaphyrin 
derivatives in methanol and for 1'C1 in mixed methanol 
water solutions. Interestingly, low temperature phosphores 
cence could not be observed for any of the compounds in 
methanol glasses. Finally, several complexes containing 
paramagnetic metal ions (e.g. Mn', Sm', and Eu', struc 
tures 5-7) were investigated. They proved to be non 
luminescent and their triplet excited states could not be 
detected with our laser flash photolysis set-up, which has a 
time resolution of ca. 10 ns. 
In methanol solution, the triplet excited states of 1-4 
were quenched by molecular oxygen with biomolecular rate 
constants of (2.6+0.2)x10 dm mol's. In aerated solu 
tion, the triplet state decay profile could be described in 
terms of a single exponential process with an average 
lifetime of (175+20) ns; thus, interaction between the triplet 
species and O, is quantitative. Laser excitation (355 nm, 80 
mJ, 10 ns) of the compound in aerated methanol gave no 
redox products (e.g. texaphyrin cation and superoxide anion) 
but, using a Ge diode, the production of 'O, was observed 
clearly from its characteristic luminescence at 1270 nm. This 
luminesce decayed with a lifetime of 12.5+0.3 us and its 
initial intensity, as extrapolated to the centre of the laser 
pulse, was a linear function of the number of photons 
absorbed by the texaphyrin complex. Comparison of the 
initial intensity with that obtained using tetrakis (4-hydrox 
yphenyl)porphyrin (THPP) as photosensitizer' under iden 
tical conditions allowed calculation of the quantum yields 
for production of singlet oxygen (1.2). The derived values 
are seen to parallel the triplet quantum yields (Table 3); the 
triplet state reaction appears to partition between generation 
of 'O (74-78%) and formation of vibrationally excited O. 
(22–26%). These 1. values compare favourably with those 
observed with porphyrins' and are much superior to values 
obtained with phthalocyanines and naphthalocyanines' due 
to the improved triplet state yields. Thus diamagnetic texa 
phyrin complexes appear to be highly efficient photosensi 
tizers for the formation of O. 
TABLE 3 
Optical and photophysical properties of 
metallotexaphyrins in CH-OH, 
Absorption Emission Dr D, t DO2 
g(nm g(nm) (+10%) (t5%) (ms) (t10%) S' 
410 732 767 0.013 0.82 67 0.61 0.74 
412 738 765 0.012 0.88 37 0.65 0.73 
417 759 780 0.01 0.88 55 0.69 0.78 
42 760 788 0.009 0.97 36 0.74 0.76 
420 760 - <0.001 ND(b) - <0.05 --- 
450 763 - <0.001 ND --- <0.05 --- 
451. 762 - <0.001 ND -- <0.05 -- 
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SiNC= bis(tri-n-hexylsiloxy)(2,3-naphthalocyaninato) silicon in benzene; see reference 4. 
In summary, the new metallotexaphrin complexes dis 
cussed here show three important optical properties which 
make them unique among existing porphyrin-like macro 
cycles. They absorb strongly in a physiologically important 
region (i.e. 730–770 nm), form long-lived triplet states in 
high yield, and act as efficient photosensitizers for the 
formation of singlet oxygen (see, e.g. FIG. 21). These 
properties, coupled with their high chemical stability and 
appreciable solubility in polar media, suggest that these 
cationic complexes could serve as viable photosensitizers in 
emerging photodynamic protocols. Preliminary in vitro 
studies of 3NO in 10% human serum, in which a signifi 
cant decrease in herpes simplex (HSV-1) infectivity and 
lymphocyte mitogenic activity are observed upon irradiation 
at 767 nm, affirm the feasibility of this approach. 
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EXAMPLE 5 
Acquired immunodeficiency syndrome (AIDS) and can 
cer are among the most serious public health problems 
facing our nation today. AIDS, first reported in 1981 as 
occurring among male homosexuals,' is a fatal human 
disease which has now reached pandemic proportions. Can 
cer, in spite of some very significant advances in diagnostics 
and treatment in recent years, remains the third leading 
cause of death in this country. Finding better ways to detect, 
treat, and reduce the transmission of these disorders are thus 
research objectives of the highest importance. 
One of the more promising new modalities currently 
being explored for use in the control and treatment of tumors 
is photodynamic therapy (PDT). This technique is based 
on the use of a photosensitizing dye, which localizes at, or 
near, the tumor site, and when irradiated in the presence of 
oxygen serves to produce cytotoxic materials such as singlet 
oxygen (O,(* )) from otherwise benign precursors (e.g. 
(O,(X)). Much of the current excitement associated with 
PDT derives from just this property: In marked contrast to 
current methods (e.g. conventional chemotherapy), in PDT 
the drugs themselves can (and should) be complete innocu 
ous until "activated' with light by an attending physician. 
Thus a level of control and selectivity may be attained which 
is not otherwise possible. 
At present, diamagnetic porphyrins and their derivatives 
are considered the dyes of choice for PDT. It has been 
known for decades that porphyrins, such as hematoporphy 
rin, localize selectively in rapidly growing tissues including 
sarcomas and carcinomas. although the reasons for this 
selectivity remain recondite. Currently most attention is 
focusing on the so-called hematoporphyrin derivative 
(HPD),’’’ an incompletely characterized mixture of 
monomeric and oligomeric porphyrins produced by treating 
hematoporphyrin dihydrochloride with acetic acid-sulfuric 
acid followed by dilute base.''' Fractions rich in the 
oligomeric species, which are believed to have the best 
tumor-localizing ability,' are marketed under the trade 
name Photofirin II(E) (PII) and are currently undergoing 
phase III clinical trials for obstructed endobronchial tumors 
and superficial bladder tumors. Here, the mechanism of 
action is thought to be largely, if not entirely, due to the 
photoproduction of singlet oxygen (O,(*)), although alter 
native mechanisms of action, including those involving 
superoxide anion or hydroxyl and/or porphyrin-based radi 
cals cannot be entirely ruled out.' 
Singlet oxygen is also believed to be the critical toxic 
species operative in experimental photosensitized blood 
purification procedures.' This very new application of 
photodynamic therapy is of tremendous potential impor 
tance: It may provide a safe and effective means of removing 
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enveloped viruses such as HIV-1, herpes simplex (HSV), 
cytomegalovirus (CMV), various forms of hepatitis, as well 
as other opportunistic blood-borne infections (e.g. bacteria 
and malaria plasmodium) from transfused whole blood. 
Given that AIDS is currently an ineffectively treated and 
usually fatal disease, the benefit of such a blood purification 
procedure would be of inestimable value. 
At present, sexual relations and needle-sharing are the 
dominant mechanisms for the spread of AIDS. An increas 
ing percentage of AIDS infections, however, are now occur 
ring as a result of blood transfusions.'" Unfortunately, 
banked blood components are essential products for the 
practice of modern medicine and as a result this method of 
transmission is not likely to be precluded by simple changes 
in lifestyle. Rather, an absolutely fail-proof means must be 
developed to insure that all stored blood samples are free of 
the AIDS virus (and ideally all other blood-borne patho 
gens). To a certain extent this can be accomplished by 
screening the donors' histories and carrying out serologic 
tests. At present, however, the serologic tests for HIV-1 are 
insufficient to detect all infected blood samples, in particular, 
those derived from donors who have contacted the disease 
but not yet produced detectable antibodies.'" In addition, 
new mutants of the AIDS virus have been detected; some or 
all of these may escape detection by current means.' Thus, 
an antiviral system is needed which removes any form of 
HIV-1 from stored blood. This is particularly important 
since a stored blood sample from one infected donor could 
potentially end up being administered to several different 
patients, in, for instance, the course of pediatric care. 
Ideally, any blood purification procedure used to remove 
AIDS virus or other blood-borne pathogens should operate 
without introducing undesirable toxins, damaging normal 
blood components, or inducing the formation of harmful 
metabolites. In general, this precludes the use of common 
antiviral systems such as those based on heating, UV irra 
diation, or purely chemical means. A promising approach is 
the photodynamic one alluded to above. Here, preliminary 
studies, carried out by collaborators at the Baylor Research 
Foundation, Dr. Matthews and his team, a others,' 
have served to show that HPD and PII, in far lower dosages 
than are required for tumor treatment, can act as efficient 
photosensitizers for the photo-deactivation of cell-free HIV 
1, HIV, hepatitis and other enveloped viruses. On the basis 
of available data, it is considered likely that the success of 
this procedure derives from the fact that these dyes localize 
Selectively at or near the morphologically characteristic, and 
physiologically essential, viral membrane ("envelope”) and 
catalyze the formation of singlet oxygen upon photoirradia 
tion. The singlet oxygen so produced is believed, in turn, to 
destroy the essential membrane envelope. This kills the virus 
and elminates infectivity. Photodynamic blood purification 
procedures, therefore, apparently rely on the use of photo 
sensitizers which localize selectively at viral membranes, 
just as more classic tumor treatments require dyes that are 
absorbed or retained preferentially at tumor sites. To the 
extent that this is true, simple enveloped DNA viruses like 
HSV-1 will prove to be good models for testing putative 
photosensitizers for potential use in killing the far more 
hazardous HIV-1 retrovirus. It is important to note, however, 
that this correspondence holds only as far as freely circu 
lating (as opposed to intracellular) viruses are concerned. 
Complete prophylactic removal of HIV-1 from blood prod 
ucts will require the destructive removal of the virus from 
within monocytes and T lymphocytes.' 
Critical as are the potential anti-tumor and anti-viral 













explored using HPD and PII, it is important to realize that 
these photosensitizers are not ideal. Indeed, this "first gen 
eration' of dyes suffers from a number of serious deficien 
cies which may in fact militate against their eventual use in 
biomedical applications. They contain a range of chemical 
species, they are neither catabolized nor excreted rapidly 
from the body, and they absorb but poorly in the red part of 
the spectrum where blood and other bodily tissues are most 
transparent. Each of these deficiencies can and does have 
important clinical consequences. For instance, the fact that 
HPD and PII do not contain a single chemically well-defined 
constituent, coupled with the fact that the active components 
have yet to be identified with certainty,’” means that the 
effective concentrations can and often do vary from prepa 
ration to preparation. Thus the dosage, and the light fluence, 
cannot necessarily be optimized and predetermined for any 
particular application. Moreover, the fact that they are not 
metabolized rapidly means that significant quantities of 
these dyes will remain in stored blood units after prophy 
lactic photoinduced HIV-1 removal and remain in patients' 
bodies long after photodynamic tumor treatment. The latter 
retention problem, in particular, is known to be quite serious: 
HPD and PII localize in the skin and induce photosensitivity 
in patients for weeks after administration.' 
It is, however, the last of the above shortcomings (the lack 
of a truly low-energy transition) that is considered to be most 
serious: Because the longest wavelength absorption maxi 
mum for these dyes falls at 630 nm, most of the incipient 
energy used in phototreatment is dispersed or attenuated 
before reaching the center of a deep-seated tumor and as a 
result little of the initial light is available for singlet oxygen 
production and therapy.'" Indeed, one study, which used 
a mouse model and a 3 mm tumor implanted beneath the 
skin served to indicate that as much as 90% of the energy is 
lost by the base of the tumor. As illustrated by the data in 
FIG. 22, taken from ref. 47, far more effective treatment 
deep-seated or large tumors might be possible if photosen 
sitizers could be developed which absorb in the >700 nm 
region, provided, of course, they retain the desirable features 
of HPD and PII (e.g. selective localization in target tissues 
and low dark toxicity). The present aspect of the invention 
involves development of such improved photosensitizers for 
use in photodynamic tumor treatment and blood purification 
protocols. 
1. Easily available 
2. Low intrinsic toxicity 
3. Long wavelength absorption 
4. Efficient photosensitizer for singlet oxygen production 
5. Fair solubility in water 
6. Selective up-take in tumor tissue and/or 
7. Showing high affinity for enveloped viruses 
8. Quick degradation and/or elimination after use 
9. Chemically pure and stable 
10. Easily subject to synthetic modification 
The list Summarizes those features which would be desir 
able in biomedical photosensitizers. Clearly, there is going 
to be some variability in the requirements, depending on 
application. For instance, photosensitizers designed for use 
in blood purification protocols should be designed to be less 
chemically stable than those used for photodynamic therapy. 
The idea being, that following irradiation the dyes will 
undergo rapid degradation or hydrolysis to yield nontoxic 
and nonactive metabolites. For tumor treatment, greater 
stability appears desirable as longer times are apparently 
required to achieve selective localization in the neoplastic 
tissues. In both cases, of course, low toxicity and good 
long-wavelength absorption and photosensitization proper 
ties are an absolute must. 
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In recent years, considerable effort has been devoted to 
the synthesis and study of new potential photosensitizers 
which might meet these desiderata. Although a few of these 
have consisted of classic dyes such as those of the 
rhodamine and cyanine classes,' many have been por 
phyrin derivatives with extended it networks.' Included 
in this latter category (See FIG. 23A, FIG. 23B, FIG. 23C 
and FIG. 23D) are the purpurins (e.g. 1) and verdins 
(e.g. 2) of Morgan and other chlorophyll-like species.'' 
the benz-fused prophyrins (3) of Dolphin et al...' and the 
sulfonated phthalocyanines and napthophthalocyanines (4) 
studied by Ben-Hur, Rodgers,' and others. Of these, 
only the napthophthalocyanines absorb efficiently in the 
most desirable >700 nm spectral region. Unfortunately, 
these particular dyes are difficult to prepare in a chemically 
pure, water soluble form and are relatively inefficient pho 
tosensitizers for singlet oxygen production, perhaps even 
acting photodynamically via other oxygen derived toxins 
(e.g. superoxide). Thus a search continues for yet a "third 
generation' of photosensitizers which might better meet the 
ten critical criteria listed above. 
It is an important aspect of the present invention that an 
improved "third generation' of photosensitizers can be 
obtained using large, pyrrole-containing "expanded porphy 
rins'. These systems, being completely synthetic, can, at 
least in principle, be tuned so as to incorporate any desired 
properties. Unfortunately, the chemistry of such systems is 
still in its infancy: In marked contrast to the literature of the 





cyanines, chlorins, etc.), there are only a few reports of 
larger pyrrole-containing systems, and only a few of these 
meet the criterion of aromaticity deemed essential for long 
wavelength absorption and singlet oxygen photosensitiza 
tion.' Indeed, to date, in addition to the present inventors' 
studies of texaphrin 5' (see FIG. 24A, FIG. 24B, FIG. 
24C, FIG. 24D and FIG. 24E), and "sapphyrin' 6, first 
produced by the groups of Woodward' and Johnson', there 
appear to be only two large porphyrin-like systems which 
might have utility as photosensitizers. These are the 
"platyrins” of LeGoff (exemplified by 22)platyrin 7)' and 
the vinylogous porphyrins of Franck (represented by 26 
porphyrin 8). Unfortunately, to date, little has been 
published on the photodynamic aspects of these materials, 
although comments have been included in the most recent 
synthetic reports which suggest that such studies are in 
progress. The present studies, however, of expanded por 
phyrins 5 and 6, indicate that an expanded porphyrin 
approach to photodynamic therapy is potentially quite prom 
ising. Interestingly, the porphycenes' (e.g. 9), a novel 
class of "contracted porphyrins' also show substantial prom 
ise as potential photosensitizers.' 
The present invention involves a major breakthrough in 
the area of ligand design and synthesis: synthesis the first 
rationally designed aromatic pentadentate macrocyclic 
ligand, the tripyrroledimethine-derived "expanded 
porphyrin'5' This compound, to which the trivial name 
"texaphyrin” has been assigned, is capable of existing in 
both its free-base form and of supporting the formation of 
hydrolytically stable 1:1 complexes with a variety of metal 
cations, including a number, such as Cd', Hg", In, Y", 
Nd", Eu", Sm", and Gd", that is too large to be accom 
modated in a stable fashion within the 20% smaller tetraden 
tate binding core of the well-studied porphyrins. In addition, 
since the free-base form of 5 is a monoanionic ligand, the 
texaphyrin complexes formed from divalent and trivalent 
metal cations remain positively charged at neutral pH. As a 
result, many of these complexes are quite water soluble-at 










To date, two X-ray crystal structures of two different Cd" 
adducts have been obtained, one of the coordinatively satu 
rated, pentagonal bipyramidal bispyridine complex;' the 
other of a coordinatively unsaturated pentagonal pyramidal 
benzimidazole complex.' Importantly, both confirm the 
planarpentadentate structure of this new ligand system and 
Support the assignment of this prototypical "expanded por 
phyrin' as aromatic. 
Further support for the aromatic formulation comes from 
the optical properties of 5. For instance, the lowest energy 
Q-type band of the structurally characterized bispyridine 
cadmium(II) complex of 5 at 767 nm (k=51,900) in CHCl, 
is both considerably more intense (by roughly a factor of 
10) and substantially red shifted (by almost 200 nm) as 
compared to that of a typical reference cadmium(II) pro 
phyrin. Of further interest is the fact that compound 5 and 
both its zinc.(II) and cadmium(II) complexes are very effec 
tive photosensitizers for singlet oxygen, giving quantum 
yields for 'O, formation of between 60 and 70% when 
irradiated at 354 nm in air-saturated methanol.' It is these 
latter remarkable properties which make these systems 
potentially ideal candidates for use in photodynamic therapy 
and blood purification protocols. 
A variety of new aromatic tripyrroledimethine-derived 
macrocyclic ligands analogous to compound 5 above now 
been prepared and more are planned. A number of these, e.g. 
10-15 (see FIGS. 25A and 25B) have already been 
synthesized and found to form metal complexes as texaphrin 
5 and many others can easily be conceived. This aspect of 
the present invention involves preparation of new analogues 
of the original texaphrin and elucidation of their chemical 
and photobiological properties of importance is the fact that, 
by making ostensibly minor substitutions, one may "tune” at 
will the energy of the lowest Q-type band. For instance in the 
sequence of cadmium(II) complexes derived from 14, 5 
and 16 (which have already been examined), this transition 
ranges from 690 to 880 nm Thus, it appears at present, as 
if the optical properties of the texaphyrin-type expanded 
porphyrins can be matched to any desired laser frequency. 
Again, this is a feature that suggests that this class of dyes 
will be well-suited for a variety of photodynamic applica 
t10lS. 
Several preliminary in vitro biological studies have been 
carried out with the cadmium(II) complexes of the 18 and 22 
TC-electron texaphyrins 14 and 5. These results, although 
limited in scope, are encouraging. For instance, both com 
plexes effect a ca. 2 log photo-killing of HSV-1 infectivity 
upon irradiation with 20 J/cm’ of light at the lowest energy 
absorption (690 nm and 767 nm, respectively), yet, impor 
tantly, neither 5 nor 14 show any appreciable dark anti 
viral activity (nor, fortunately, do they show much evidence 
of general cytotoxicity in the absence of light). In addition, 
the 22 TC-electron cadmium-containing texaphyrin 5 has 
been shown by both absorption and emission measurements 
to localize selectively on lymphocytes. This latter result, in 
particular, augurs well for the eventual use of these materials 
in prophylactic photodynamic anti-AIDS blood-treatment 
programs. The 2 log decrease in HSV-1 activity achieved 
with the texaphyrin systems studied to date is not yet 
sufficient to completely design a viable protocol: Both HPD 
and PI, as well as sapphyrin (6), reprepared by literature 
methods' provide about a 5 log decrease in viral activity 
under similar lightfluence when irradiated at the appropriate 
lowest energy transition (630 and 690 nm, respectively). 
Although a mechanistic comparison with the incompletely 
characterized hematoporphyrin-derived systems is difficult, 
a direct structural correspondence exists between the tripyr 
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roledimethine-derived cadmium(II) texaphyrin and free 
base sapphyrin systems: The main difference is in overall 
charge on the photosensitizer. It may thus be that these two 
macrocycle types are bound to the virus envelope in a 
different manner; perhaps the sapphyrin "intercalates' into 
the lipid layer and the charged metallotexaphyrin sits on the 
surface of the membrane and as such could suffer from 
deleterious aggregations (which would lower singlet oxygen 
production). The critical observational difference between 
these two closely related systems (texaphyrin vs. sapphyrin) 
suggests that small structural differences may be reflected in 
significant functional effects. In addition, these experimental 
findings suggest that: 1) The free-base texaphyrin system 
should be a far more efficient photosensitizer for in vitro and 
in vivo applications that the cadmium complexes studied so 
far, and that 2) adjusting the substituents on the texaphyrin 
periphery should serve to alter the key biodistribution prop 
erties of the metalated and metal-free systems. Even if all 
attempts to augment the photodynamic antiviral efficiency of 
texaphyrin meet with failure (a result we consider highly 
unlikely), it is probable that this new photosensitizer will 
find applications in more classic tumor-treating procedures: 
the 18 TC-electron cadmium-containing macrocyclic system 
14, for instance, has already been shown to effect a roughly 
4 log photo-kill of Daudi-strain leukemic cells. 
The synthesis of texaphyrin 5 is summarized in FIG. 
26A and FIG. 26B. It involved three major steps. The first is 
the synthesis of the tripyrrane 19. This crucial intermediate 
is obtained directly as the result of the simple acid-catalyzed 
condensation between pyrroles 17 and 18. Following 
deprotection and formylation the key diformyl tripyrrane 
precursor 21 is obtained in yields exceeding 80% based on 
17. Condensation of this tripyrrane with O-phenylenedi 
amine constitutes the second critical step in the synthetic 
pathway. Fortunately, this reaction proceeds in virtually 
quantitative yield and gives the sphybridized form of the 
"texaphyrin” skeleton, 22, directly." The final critical step 
then involves oxidation and, as appropriate, concurrent 
metal binding. In the case of Cd'", Hg', and Zn'", the 
aromatic, sp’ hybridized, form of the macrocycle (5) is 
obtained in roughly 25% yield by simply stirring the starting 
sphybridized precursor (22) with the appropriate salt in 
the presence of oxygen.' Such a simple metal insertion and 
oxidation procedure, however, fails for cations of the lan 
thanide series. Here, a combination of metal salt, proton 
sponge(E) (N,N',N',N"-tetramethyl-1,8-diaminonaphtha 
lene), and oxygen are required to effect oxidation and metal 
insertion. Interestingly, the use of a proton sponge alone 
gave the free-base form of the ligand directly, but unfortu 
nately in only ca. 10% yield. Efforts to optimize this latter 
yield are still in progress. 
By using a variety of other substituted diamines and/or 
diformyl tripyrranes, it has already proved possible to gen 
erate a range of other tripyrroledimethine-derived macro 
cycles including compounds 10-16 (FIG. 25A, FIG. 25B, 
and FIG. 25C), 1-7,8,9, (FIG.31A, FIG.31B, and FIG. 
31C), 23, 25, 26 (FIG. 27A and FIG. 27B) those skilled 
in the art will be able to prepare many more. For instance, 
by using the appropriate diamine and/or diformyl tripyrrane, 
those skilled in the art will be able to generate the modified 
texaphyrins 24, 27-30, shown in FIG. 27A, FIG. 27B, 
FIG. 27C, and FIG. 27D, where in the cases of the gener 
alized structures of 29 and 30, the substituents R, R2, R, 
R, and Rs may be separately and independently H, alkyl, 
amino, hydroxy, alkyoxy, carboxy, carboxamide, ester, 
amide, sulfonato, or substituted alkyl, substituted alkoxy, 












be any di- or trivalent metal cation with the charge, n, 
adjusted as appropriate as an integral value between -5 and 
+5. Here, as would be apparent to one skilled in the art, the 
charge n nould be adjusted so as to account for the choice of 
metal, M the pH under consideration, and the substituents 
R-Rs. For instance, if R=carboxyl and R-Rs=alkyl and 
the metal, M=Gd", and the solution pH=7 (so that R=CO, 
), the charge n would be zero. 
A further advantage of developing a wide variety of 
solubilized texaphyrins is that many of these would be 
suitable for further functionalization. For instance, treatment 
of texaphyrins 7, 25, 26, 27, 28, or 29 with thionyl 
chloride or p-nitrophenol acetate would generate activated 
acyl species suitable for attachment to monoclonal antibod 
ies or other biomolecules of interest. Alternatively, standard 
in situ coupling methods (e.g. DCCI) could be used to effect 
the same sort of conjugation. In either case, the ability to 
attach and deliver a potent photosensitizer or active radio 
isotope directly to a tumor locus could have tremendous 
potential benefit in the treatment and/or detection of neo 
plastic disorders.' 
All of the texaphyrin systems prepared to date, and all the 
new target systems proposed above, involve an imine 
containing macrocyclic core. The use of such a linking 
group offers both advantages and disadvantages. The pri 
mary advantage is that macrocyclic systems containing such 
subunits are easy to prepare and generally act as effective 
ligands (this is certainly true for texaphyrin!). On the other 
hand, they are thermodynamically unstable with regards to 
hydrolysis, although, at least in the case of texaphyrin 5, 
this is less of a problem than one might expect. For instance, 
the half-lives for imine hydrolysis of the best-studied cad 
mium-containing complex of 5 and gadolinium complexes, 
2 and 7 (FIG. 17B) are both in excess of 30 days at pH 7 
and several hours at pH 2. Nonetheless, applications could 
be envisioned where greater stability might be required. For 
this reason the synthesis of the two methine-linked texaphy 
rin analogues 31 and 32, in which the weakest CH=N link 
has been replaced by a more robust CH=CH subunit (See 
FIG. 28A and FIG. 28B) is an aim of this invention. It is an 
expectation that compounds 31 and 32 may be prepared 
using either standard Wittig-based ring closures, which have 
proved useful in the synthesis of large, furan-containing 
annulenes," or via McMurry-type couplings, such as those 
that have recently proved useful in the synthesis of por 
phycenes.' 
Once in hand, all new texaphyrin systems will be char 
acterized fully using normal spectroscopic and analytical 
means, including, where possible X-ray diffraction methods. 
In addition, a complete analysis of the optical properties will 
be made for all new systems under a range of experimental 
conditions including some designed to approximate those 
which might pertain in vivo. Initial measurements such as 
simple recording of the optical absorption and emission 
spectra will be carried out in the P.I.'s laboratory. More 
detailed analyses, including triplet lifetime and singlet oxy 
gen quantum yield determinations, will be carried out. The 
objective of this part of the proposed research program is to 
obtain a complete ground and excited state reactivity profile 
for each and every new texaphyrin produced. Questions 
such as when is singlet oxygen production maximized, how 
is the quantum yield for its formation influenced by the 
position of the lowest energy (Q-type) transition, whether 
aggregation is more prevalent in certain solvents or in the 
presence of certain biologically important components (e.g. 
lipids, proteins, etc.), and, finally, whether significant dif 
ferences in in vitro optical properties are derived from the 
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use of elaborated texaphyrins bearing cationic, anionic, or 
neutral substituents all will be thus answered. 
Once the above complexes are made, screening experi 
ments are carried out. Standard in vitro protocols will be 
used to evaluate the in vitro photo-killing ability of the 
texaphyrin derivatives in question. For instance, the dyes of 
choice will be administered in varying concentrations to a 
variety of cancerous cells and the rate of replication deter 
mined both in the presence and absence of light. Similarly, 
dyes of choice will be added to standard viral cultures and 
the rate of growth retardation determined in the presence and 
absence of light. Where appropriate, a variety of solubilizing 
carriers will be used to augment the solubility and/or mono 
meric nature of the texaphyrin photosensitizers and the 
effect, if any, that these carriers have in adjusting the 
biodistribution properties of the dyes will be assessed (using 
primarily fluorescence spectroscopy). It should be stressed, 
of course, that in all cases appropriate control experiments 
will be carried out with normal cells so that the intrinsic dark 
and light toxicity of the texaphyrins may be determined. 
From a generalized set of in vitro experimental proce 
dures, it is expected that a clear picture of the photodynamic 
capabilities of the texaphyrin system will emerge. Again, as 
above, key questions about structure and reactivity will be 
addressed and answered in what is (hopefully) an unam 
biguous fashion. In addition, some preliminary toxicity and 
stability information will begin to emerge from these in vitro 
experiments. Here questions of interest include how long the 
texaphyrin system is holding up under physiological condi 
tions and whether the nature of the central metal influences 
this stability. Equally, or perhaps more important is the 
question of whether the central cation is affecting cytotox 
icity. As discussed in papers published by the present 
inventors,' it is not possible to remove the larger bound 
cations (e.g. Cd" or Gd) by simple chemical means (Zn, 
however, appears to "fall out' with ease). Moreover, pre 
liminary results suggest that the best-studied cadmium(II)- 
containing texaphyrin complex 5 is not appreciable cyto 
toxic. Nonetheless, the question of intrinsic toxicity is one of 
such central importance that the cytotoxicity of all new 
systems will be screened in vitro and, where deemed appro 
priate, further in vivo toxicity studies will also be carried 
Out. 
Once in vitro screening experiments are complete, 
samples of potential photosensitizers that look particularly 
promising will be selected for further development. Those 
that possess the best combination of stability and photody 
namic ability for use in blood treatment protocols will be 
furtherevaluated in flow system using whole blood samples. 
Those that look promising for tumor treatment will be 
subjected to further animal screening. 
This aspect of the present invention involves the coordi 
nation and photochemical properties of tripyrroledimethine 
derived "texaphyrins", a new class of "expanded prophy 
rins', the first members of which have been recently 
prepared and characterized in our laboratory. It is expected 
that these basic studies will lead to the development of 
viable procedures of removing HIV-1 and other enveloped 
viruses from transfused blood as well as improved means of 
detecting and treating tumors. The long range goals exem 
plified here are to: 
1. Synthesize further safe and efficient photosensitizers 
for use in killing human immunodeficiency virus (HIV 
l) and other enveloped viruses in blood, which operate 
without harm to normal blood components. 
2. Develop new safe and effective photosensitizers for use 















The approach to these long range objectives centers 
around the preparation and use of suitably modified tripyr 
role-dimethine derived texaphyrin-type expanded porphy 
rins. This is an essential first step towards the realization of 
the above goals. Specific extensions of the present invention 
include: 
1. Explore further the coordination and general chemical 
properties of our original texaphyrin and existing ana 
logues and obtain a complete solubility, stability, and 
reactivity profile for those complexes deemed likely to 
be of greatest biomedical interest. 
2. Synthesize simple analogues of the currently available 
texaphyrins with cationic, anionic, or neutral substitu 
ents and study how such modifications alter the water 
solubility and biodistribution properties of these 
expanded porphyrins. 
3. Make analogues of texaphyrin which contain reactive 
nucleophilic or electrophilic substituents suitable for 
conjugation to monoclonal antibodies or other biomol 
ecules of potential interest. 
4. Prepare new texaphyrin-type aromatic macrocycles in 
which the key imine (CH=N) functionality has been 
replaced with a presumably more robust methine 
(CH=CH) linkage. 
5. Carry out complete photochemical studies of all new 
texaphyrins so as to determine unambiguously those 
factors (e.g. ) which maximize singlet oxygen 
production. 
6. Test the in vitro photodynamic tumor and virus killing 
efficiency of the new texaphyrins prepared in the course 
of the synthetic phase of this project. 
7. Test the in vivo photodynamic anti-tumor properties of 
the more promising texaphyrins synthesized and 
screened as outlined above. 
Literature citations in the following list are incorporated 
by reference herein for the reasons cited. 
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EXAMPLE 6 
One aspect of the utility of the present invention is 30 
exemplified by use of complexes described herein for pho 
ton-induced deactivation of viruses and virally infected or 
potentially infected encaryotic cells. The general photode 
activation method used in this example was developed by 
the Infectious Disease and Advanced Laser Applications 35 
Laboratories of the Baylor Research Foundation, Dallas, 
Tex. and is a subject of a U.S. patent application filed Jun. 
25, 1987 by Millard Monroe Judy, James Lester Matthews, 
Joseph Thomas Newman and Franklin Sogandares-Bernal 
(assigned to the Baylor Research Foundation, Dallas, Tex.). 
The efficiency of some of the porphyrin-like macrocycles 
in photosensitized inactivation of Herpes Simplex Virus 
Type 1 (HSV-1) and of human lymphocytes and monocytes, 
both peripheral mononucleated vascular cells (PMC) and 
cellular hosts of HIV-1 has been initiated. Previous studies 45 
of viral inactivation using the macrocyclic photosensitizers 
dihematoporphyrin ether (DHE) or hematoporphyrin deriva 
tive (HPD) have shown that with the porphyrins, only those 
viruses studied which are enveloped or possess a membra 
neous coat are inactivated. The enveloped viruses studied 50 
include HSV-1, cytomegalovirus, measles virus', and the 
human immunodeficiency virus HIV-1'. 
The photosensitized inactivation of Herpes Simple Virus, 
Type 1 (HSV-1) was investigated in culture medium using 
40 
various macrocycles of the present invention. Results are 55 
listed in Table 4. 
TABLE 4 
Herpes Simplex Virus I Inactivation with Assymmetric 60 
Expanded Porphyrin Macrocycle Complexes 
%. Survival Wiral 
Complex** Conc. (M) Infectivity 
3A 20 2 
O 8 65 
2.5 20 
TABLE 4-continued 
Herpes Simplex Virus I inactivation with Assymmetric 
Expanded Porphyrin Macrocycle Complexes 
% Survival Viral 
Complex** Conc. (M) Infectivity 
0.25 100 




14(where M-Cd) 16.0 3 
4.0 50 
0.40 100 
*All light irradiation at * max absorption and to give a light fluence of 10 
J/cm 
**Structural formulas in FIG. 4B and FIG. 25A. 
The three cadmium-containing macrocycles (3, 10 
(where M is Cd), and 14 (where M is Cd)) at concentrations 
of 20 uM demonstrated 290% viral inactivation as judged 
by viral plaque assay. 
The macrocycle photosensitizing studies employed envel 
oped HSV-1 as the model for screening based on its ease of 
propagation and assessment of infectivity in cell culture. The 
screening procedure for photoinactivation of HSV-1 was 
similar to the methods previously described. Essentially, 
selected macrocycles at different concentrations were added 
to a cell-free suspension of 10 PFU/ml of HSV-1. The viral 
suspensions were irradiated at the optimal absorption wave 
length of the selected dye at different light-energy densities. 
Controls consisted of (1) nonirradiated virus, (2) virus 
irradiated in the absence of macrocycle, and (3) virus treated 
with selected concentrations of macrocycle and maintained 
in the dark. All samples were then assessed for viral infec 
tivity by determining the number of PFU/ml in Vero cells. 
Viral suspensions were serially diluted and subsequently 
absorbed onto Vero cell monolayers for 1% hours at 37 C. 
An overlay medium was added and the cells incubated at 
37C. for 3-4 days. The overlay medium was then removed, 
the monolayers fixed with methanol and tinctured with 
Giemsa, and individual plaques counted under a dissecting 
microscope. Uninfected cell cultures also were exposed to 
the macrocycle complexes to rule out direct cytotoxic 
effects. 
The inactivation of PMC's in the absence and presence of 
light after exposure to concentrations of complex 3A in 
whole human plasma ranging from 0.015 to 38 uM is shown 
in FIG. 29 and FIG. 30. Inactivation was judged by mito 
genic assay. Toxicity onset with 3 (see FIG. 4B) and 1 (see 
FIG. 19) in the absence of light was between 0.15 and 1.5 
M (FIG. 29). As shown by mitogenic assay in FIG. 30, 
aerobic photosensitization of cells exposed to 3 at 0.15uM 
concentration and 20joules/cm’ of 770 nm wavelength light 
caused significant inhibition of the cellular division of 
PMC's. Moderate increase in either photosensitizer concen 
tration or light dosage is expected to result in essentially 
complete cellular inactivation. 
The results to date, some of which are summarized herein, 
indicate strongly that the expanded porphyrin-like macro 
cycles of the present invention should be efficient photosen 
sitizers for free HIV-1 and infected mononuclear cells as 
well. Altering the polarity and electrical charges of side 
groups of these macrocycles is anticipated to alter markedly 
the degree, rate, and perhaps site(s) of binding to free 
enveloped viruses such as HIV-1 and to virally-infected 
peripheral mononuclear cells. These substituent changes are 
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also expected to modulate photosensitizer take-up and pho 
tosensitization of leukemia or lymphoma cells contaminat 
ing bone-marrow as well as by normal cells of the marrow. 
References in the following literature incorporated by 
reference herein for the reasons cited. 
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EXAMPLE 7 
This example summarizes certain of the basic five-coor 
dinate (pentadentate), expanded porphyrin compounds and 
complexes of the present invention and their derivatives 
which have been synthesized. In FIG. 31A, FIG. 25A and 
FIG. 25B, compounds 1-7, 14 and 15 are shown. 
Variations include changes in the ortho-phenylene-diamino 
substituent, namely R and R and in the nature of the 
starting diamine itself. When both R' and R on the ortho 
phenylene diamino substitutent are hydrogen as in com 
pound 1 the basic structure of texaphyrin is shown; These 
R and R substituents may also both be methyl, CH, 
(compound 2). Additionally when R is H, R may be 
chloride (compound 3); bromine (compound 4); nitro 
(compound 5); methoxy (compound 6); or carboxy (com 
pound 7). When M is hydrogen, the complex has a charge 
of 0 (n=0). When M is a divalent metal such as mercury', 
cadmium', zinc', cobalt' or manganese"; the charge of 
the complex will be +1 (n=1). When M is a trivalent metal 
cation such as europium", neodynium", samarium", lan 
thanum", gadolinium', indium' or yttrium' the charge 
of the complex will be +2 (n=2). For the complexes marked 
with a single asterisk (1 and 2) all metals, divalent or 
trivalent mentioned above have been included in various 
formed complexes. Complexes with a double asterisk 
(3-6) have been synthesized as either the zinc or cadmium 
derivative (M=Zn or Cd; n=1). While many other usable 
compounds are mentioned in other sections of this applica 
tion, or could be readily synthesized by those of skill in the 
art from the directions included herein, the particular ones 
mentioned in this Example are thought to be especially 
useful for many purposes, for example, those involving 
purifying biological samples of viruses, particularly retro 
viruses. These compounds should also be useful for pro 
cesses such as, for example, photodynamic cancer therapy, 
magnetic resonance imaging (MRI) enhancement and anti 
body functionalization as mentioned elsewhere herein. 
EXAMPLE 8 
Magnetic Resonance Imaging Enhancement 
In many respects the key to cancer control lies as much, 
if not more, in early detection and diagnosis as it does in 
subsequent therapeutic management. New techniques which 
allow neoplastic tissue to be observed and recognized at an 
early stage of development thus have a critical role to play 
in the battle against these disorders. One such promising 














Although quite new, this noninvasive, apparently innocuous 
method, is not firmly entrenched as a diagnostic tool of 
prime importance, complementing or, in some cases, Sup 
planting computer assisted X-ray tomography as the method 
of choice for solid tumor detection. 
The physical basis of current MRI methods has its origin 
in the fact that in a strong magnetic field the nuclear spins 
of water protons in different tissues relax back to equilibrium 
at different rates, when subject to perturbation from the 
resting Boltzman distribution by the application of a short rf 
pulse.” For the most common type of spin-echo imaging, 
return to equilibrium takes place in accord with equation 1 
and is governed by two time constants T and T2, the 
longitudinal and transverse relaxation times, respectively. 
Here, SI represents the signal intensity, H is the concen 
tration of water protons in some arbitrary volume element 
(termed a voxel), HO a motion factor corresponding to 
motion (if any) in and out of this volume element, and T 
and T are the echo-delay time and the pulse-repetition 
times, respectively. The various pulse sequences associated 
with obtaining an MRI image thus correspond to choosing 
T and T by setting the times associated with (and between) 
the excitation and interrogation rf pulses (the first to perturb 
the system, the second to determine the extent of return to 
equilibrium) and determining SI, which, as illustrated above, 
is function of the particular T and T values in force. Since 
both T and T are a function of the local (bulk) magnetic 
environment, and as such are a function of the particular 
tissue in which the water proton is situated, differences in 
these values (and hence SI) allow for image reconstruction. 
Of course, only when these local, tissue-dependent, relax 
ation differences are large can tissue differentiation be 
effected. 
In practice for biological systems, T values are very short 
(and T and T are chosen to accentuate this situation). Thus 
it is differences in the longitudinal time constant (T) which 
dominate relaxation effects and relative signal intensity: 
Decreases in T correspond to increasing signal intensity. 
Any factors, therefore, which will serve to decrease T 
selectively for a particular tissue or organ will thus lead to 
increased intensity for that area and better contrast (signal to 
noise) relative to the bulk animal background. This is where 
paramagnetic MRI contrast agents come into play." 
It has been known since the earliest days of magnetic 
resonance spectroscopy that paramagnetic compounds, con 
taining one or more unpaired spins, enhance the relaxation 
rates for the water protons in which they are dissolved. The 
extent of this enhancement, termed relaxivity, is, in the 
absence of colligative interactions, given by R (in units of 
M-'s- or mM-'s-) in eq. 2." 
(lfT)=(l/T)-R,Mil, 2 (2) 
Here, (1/T) is the reciprocal of the observed relaxation 
time in the presence of a paramagnetic species M, and 
(1/T) is the observed relaxations time in its absence. The 
relaxivity of any given paramagnetic species, i.e., metal 
complexes for MRI enhancement, is dependent on the 
magnitude of the dipole-dipole interactions between the 
electron spin (on the metal) and the proton spin (on the 
water). The extent of this interaction is strongly dependent 
on the nature of the interaction between the paramagnetic 
complex and the water molecule in question. Traditionally, 
it has proved convenient to define both "inner sphere' and 
"outer sphere" contributions to the total relaxivity R. The 
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former account for water molecules which participate 
directly in the coordination sphere of the metal; the latter for 
all other loose interactions (e.g. hydrogen bonding and 
translational diffusion of waters bound in the second coor 
dination sphere). Where chemically viable, it is, in general, 
inner sphere relaxation which dominates R. For this inter 
action, the contribution to the longitudinal relaxation is 
given by equation 3." 
(1/T) (inner sphere-PM/T Milm) (3) 
Here, P is the mole fraction of metal ion, q is the number 
of bound water molecules, t is the lifetime of the bound 
water, and T is the relaxation time of the bound water 
protons. The value of this latter term is approximated by the 
Solomon-Bloembergen equations (eqs. 4-6) which account 
for both dipole-dipole ("through space') and contact 
("through-bond") terms." 
1 2 Yi'g'S(S+ 1) 7tc. (4) 
T T 15 6 (1 = w?t2) 
3t + (2/3)S(S+ 1) A2L/h)? ow- -- 
(1 = wit?) (1 + wt.) 
Here, Y is the proton gyromagnetic ratio, g the electronic 
g-factor, S the total electron spin of the paramagnetic ion, B 
the Bohr magneton, r the water proton-metal ion distance, 
A27t/h) the electron-nuclear hyperfine coupling constant, 
and w and w the electronic and proton Larmor precession 
frequencies, respectively. The dipolar and scaler correlation 
times t and t are given by: 
littliTilli-l/R (5) 
littl/T+1/t (6) 
where, T is the longitudinal electron spin relaxation time 
and t the rotational tumbling time of the entire water 
complex ensemble. More elaborate theoretical treatments 
are available to account for collisional relaxation effects and 
other factors which would perturb the static zero-field split 
ting of the electronic sublevels in inner sphere relaxation 
pathways. Detailed analyses are also available to account 
for contributions from outer sphere mechanisms. Nonethe 
less, for the sake of the present discussion, the simple 
Solomon-Bloembergen equations given above will suffice: 
They illustrate the key physical features required for a good 
paramagnetic contrast agent. 
From a physical point of view, MRI contrast agents 
require species that are highly paramagnetic (so that the 
magnetic moment term S(Shi) is large), possess large T's, 
and display large rotational tumbling times (t). In addition, 
an ideal contrast agent should also bind one or more water 
molecules (so that the inner sphere relaxation mechanisms 
are operative) and exchange these waters at a rate (1?t) that 
is optimal.'' with the exception of t, which is often set 
more by the effective viscosity of the local environment (i.e. 
is the complex "stuck” to a slowly rotating protein'?') than 
by the choice of complex, all of these factors may be 
influenced by the choice of basic paramagnetic cation and by 
subsequent ligand design.' This ligand design, which 
constitutes a major thrust in current MRI research, is, of 
course, also subject to very stringent biological require 
ments: Not only must the putative contrast agent be highly 
paramagnetic and achieve good relaxation enhancement, it 
must also be nontoxic at the dosages administered, stable in 
vivo, excreted quickly after diagnosis is complete, and, of 
course, show desirable tissue localizing abilities. Taken 














Indeed, at present, only one paramagnetic MRI contrast 
agent is in clinical use, the bis(N-methylglucamine) salt of 
Gd(III) diethylenetriaminepentaacetate, (MEG), 
(Gd(DTPA)(HO) (c.f. structure 10)''' marketed by Ber 
lex Laboratories. This dianionic complex localizes selec 
tively in extracellular regions, and is being used primarily in 
the visualization of the capillary lesions associated with 
cerebral tumors.' In Gd(DTpA)(HO), one molecule 
of water is bound in the first (inner) coordination sphere and 
at 37° C. in water this complex displays a relaxivity of 3.7 
mM-'s- at 20 MHz.' In marked contrast to the simple 
Gd(III) complex of EDTA, for which log K=17.4 at 25° 
C,' the DTPA complex appears to be sufficiently ther 
modynamically stable (log K =22.5 at 25°C.?' so as to 
be kinetically stable under physiological conditions and is 
apparently excreted intact through the kidneys within sev 
eral days of administration.' These desirable features not 
withstanding, it is clear that other contrast agents with 
superior kinetic stability, better relaxivity, lower net charge 
(which would lower the osmolality and hence pain threshold 
of the administered solutions), and/or different tissue local 
izing capabilities would be desirable for clinical use. Indeed, 
in a recent review on the subject, Lauffer states that: "New 
synthetic methods toward kinetically inert complexes, espe 
cially those of Gd(III), need to be developed. These prefer 
ably should be versatile enough to allow for specific sub 
stitutions on the complex that may modulate its properties.' 
To date, in fact, considerable effort has been devoted to 
the development of new potential MRI contrast agents.'" 
Most of this work has centered around preparing new 
complexes of Gd(III)'''. The emphasis on Gd(III) 
salts stems from the fact that this cation, with 7 unpaired 
f-electrons, has a higher magnetic moment than other para 
magnetic cations such as Fe(III) and Mn(II). Thus, all 
other things being equal, complexes of Gd(III) would be 
expected to be superior relaxation agents than those derived 
from Mn(II) or Fe(III). In addition, both iron and, to a lesser 
extent, manganese are sequestered and stored very effi 
ciently in humans (and many other organisms) by a variety 
of specialized metal-binding systems. Moreover both iron 
and manganese are capable of existing in a range of oxida 
tion states and are known to catalyze a variety of deleterious 
Fenton-type free-radical reactions.' Gadolinium(III), 
which suffers from neither of these deficiencies thus appears 
to offer many advantages. Unfortunately, as is true for 
Fe(III) and Mn(II), the aqueous solution of Gd(III) is too 
toxic to be used directly MRI imaging at the 0.01 to 1 mM 
concentrations required for effective enhancement.' Hence 
the emphasis is on developing new agents which, as is true 
for DTPA, form hydrolytically stable complexes in vivo 
with Gd(II) and/or other paramagnetic cations. A number of 
such ligands, including the very promising DOTA''' and 
EHPG' systems, are now known (c.f. reference 5 for an 
extensive review). In almost all cases, however, reliance is 
made on the same basic philosophical approach. Specifi 
cally, for Gd(III) binding, carboxylates, phenolates, and/or 
other anionic chelating groups are being used to generate 
intrinsically labile complexes of high thermodynamic sta 
bility in the hope that such high thermodynamic stability 
will translate into a kinetic stability that is sufficient for in 
vivo applications. Indeed, little effort is currently being 
devoted to the preparation of nonlabile Gd(III) complexes 
that would in and of themselves enjoy a high kinetic 
stability. The problem seems to be quite simply that such 
systems are hard to make. For instance, unlike the transition 
metal cations which are bound well to porphyrins (a syn 
thetically versatile ligand which is readily subject to modi 
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fication and which, at least for Mn(III)TPPS), and other 
water soluble analogues,'" shows good relaxivity and 
good tumor localizing properties), Gd(III) forms only weak 
and/or hydrolytically unstable complexes with porphyrins, 
''' although other simple macrocyclic amine- and 
imine-derived ligands' will support stable complexes 
with certain members of the lanthanide series and do show 
some promise, as yet unrealized, of acting as supporting 
chelands for Gd(III)-based MRI applications. It is a premise 
of the present invention that nonlabile porphyrin-like Gd(III) 
complexes can be generated using an "expanded porphyrin' 
approach and that once made these complexes will prove to 
be useful contrast agents for MRI applications. In fact, 
texaphyrin is capable of stabilizing complexes with a variety 
of di- and trivalent cations, including Cd', Hg, Y", In", 
and Nd". The observation that a hydrolytically stable Nd" 
complex may be supported by texaphyrin bodes well for the 
use of texaphyrins in various gadolinium(III)-based MRI 
applications. Unfortunately, as explained in greater detail in 
Example 4, all efforts to date to isolate a stable Gd" 
complex from texaphyrin in good yield in good yield have 
met with failure. It is suspected that this is because the 
complex is actually so water soluble that standard work-up 
methods fail. Consistent with this supposition is the fact that 
fully characterized Sm', Eu", and Gd" (as well as Y') 
complexes have been prepared from the more hydrophobic 
dimethyl-texaphyrin. These complexes are obtained in 
roughly 25% yields from the corresponding reduced (meth 
ylene bridged) macrocyclic precursor using the standard 
metal insertion and oxidation conditions discussed below 
and in Examples 1 and 2. Importantly, all of these complexes 
are soluble in 1:1 methanol-water mixtures and all are quite 
stable under such potentially decomplexing conditions. The 
half-life of the Gd" complex in 1:1 methanol-water at room 
temperature, for instance, is over 5 weeks. Thus it is possible 
to use a texaphyrin-type approach to generate hydrolytically 
stable gadolinium(III) complexes (something that cannot be 
achieved using simple porphyrins.' Given this critical 
result, further modifications of the texaphyrin skeleton 
which should allow preparation of stable Gd" complexes 
with improved water solubility or better biodistribution 
properties. In addition, by using suitable anionic side-chains, 
it should be possible to prepare neutral complexes with no 
net overall charge. Such complexes would display a lower 
osmolality in aqueous solution. This would reduce the pain 
associated with their administration and have positive clini 
cal consequences. Thus the texaphyrin approach to MRI use 
of contrast agent development looks promising. 
Literature citations in the following list are incorporated 
by reference herein for the reasons cited. 
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Radioisotopes have long played a central role in the 
detection and treatment of neoplastic disorders. Consider 
able research therefore continues to be devoted to improving 
their efficacity in medical applications. One of the more 
promising approaches in doing so involves attaching radio 
isotopes to tumor-directed monoclonal antibodies and their 
fragments. Such monoclonal antibodies and their fragments 














therefore serve as "magic bullets' and allow the direct 
transport of radioisotopes to neoplastic sites thus minimizing 
whole body exposure to radiation. Considerable research is 
now being carried out along these lines (see references 2-11 
for general reviews). Much, but certainly not all, is focusing 
on the use of bifunctional metal chelating agents. It is this 
approach to radioimmunodiagnostics (RID) and therapy 
(RIT) that is most closely related to the present invention. 
Bifunctional metal chelating agents for use in antibody 
conjugate-based treatment and diagnostic applications must 
satisfy two critical criteria: They must be capable of binding 
the radioisotope of interest and of attachment to the targeted 
antibody. Thus, these bifunctional chelating agents must 1) 
have functional groups suitable for conjugation to the anti 
body, 2) form covalent linkages that are stable in vivo and 
which do not destroy the immunological competence of the 
antibody, 3) be relatively nontoxic, and 4) bind and retain the 
radiometal of interest under physiological conditions.'' 
The last of these conditions is particularly severe. In contrast 
to MRI imaging where small concentrations of decomplexed 
cation can perhaps be tolerated, the potential damage arising 
from "free' radioisotopes, released from the conjugate, can 
be very serious. Thus, for radioimmunological work, the 
condition of nonlability must be strictly enforced. On the 
other hand, only nanomole concentrations of isotopes, and 
hence ligand, are generally required for RID and RIT 
applications, so that the concerns associated with intrinsic 
metal and/or free ligand toxicity are considerably relaxed. 
Needless to say, the above conditions must be met for 
each and every isotope considered for RIT and RID work. 
Thus, from the point of view of ligand design and synthesis, 
the problem becomes one of identifying an isotope of 
medical advantage, designing a suitable ligand and attaching 
it to the antibody of choice either before or after metal 
binding. Historically, there has been a trade-off between 
choosing an ideal isotope and one that can be readily 
complexed with existing difunctional conjugates. 
For the purposes of imaging, an ideal isotope should be 
readily detectable by available monitoring techniques and 
induce a minimal radiation-based toxic response. In practice 
these and other necessary requirements implicate the use of 
a Y-ray emitter in the 100 to 250 KeV range, which 
possesses a short effective half-life (biological and/or 
nuclear), decays to stable products, and, of course, is readily 
available under clinical conditions. ' To date, therefore, 
most attention has focused on 'I (t=193h), 'I(t= 
13h), ''"Tc(t=6.0 h), ''Ga(t=78 h), and 'In(t=67.4 
h) which come closest to meeting these criteria.' Each of 
these enjoys advantages and disadvantages with respect to 
antibody labeling for RID. 'I and 'I, for instance, are 
easily conjugated to antibodies (and other proteins) via 
simple electrophilic aromatic substitution of tyrosine resi 
dues.'" As a result, these isotopes have seen wide use in 
immunological-based applications (RIT as well as RID). 
Unfortunately, such methods of conjugation are not particu 
larly robust under physiological conditions (metabolism of 
'I or 'I labeled proteins, for instance, produces free 
radioactive iodide anion) and as a result can lead to a fair 
concentration of radioactivity at sites other than those tar 
geted by the antibody-derived “magic bullet'.' This prob 
lem is further exacerbated by the fact that the half-lives of 
both 'I and 'I are relatively inconvenient for optimal use, 
being too long and too short, respectively, and the fact that 
I is also a B emitter. '"Tc, "Ga, and 'In all suffer 
from the disadvantage that they cannot be bound directly to 
the antibody in a satisfactory fashion and require the use of 
a bifunctional conjugate. The chemistry of such systems is 
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furthest advanced in the case of '"Tc, and a number of 
effective ligands, are now available for the purpose of '"To 
administration.'''This particular radioisotope, however, 
suffers from the serious disadvantage of having a very short 
half-life which makes it technically very difficult to work 
with. Both 'Ga and 'In have longer half-lives. In addition, 
both possess desirable emission energies. Unfortunately, 
both are "hard' cations with high charge density in their 
most common trivalent forms. Applications of these radio 
isotopes in RID therefore requires the use of ligands which 
are capable of forming stable, nonlabile complexes with 
these cations under physiological conditions. Although con 
siderable effort has been devoted to the development of 
DTPA-like systems' which would be suitable for 'In" 
(and, perhaps, ''Ga") binding and antibody functionaliza 
tion, in all cases the complexes formed are too labile for safe 
and effective clinical use.' Indeed, at the present time, no 
suitable ligands exist for either 'In or'Ga" which form 
stable nonlabile complexes and which might be suitable for 
radioimmunological applications. As described elsewhere 
herein texaphyrin forms a kinetically and hydrolytically 
stable complex with In". Such a ligand system could be 
elaborated and serve as the critical core of a bifunctional 
conjugate for use in 'In-based RID. 
Many of the same considerations hold true for radioiso 
tope-based therapy as do for radioisotope-based diagnostics: 
An ideal isotope must also be readily available under clinical 
conditions (i.e. from a simple decay-based generator),’ 
possess a reasonable half-life (i.e. on the order of 6 hours to 
4 weeks), and decay to stable products. In addition, the 
radioisotope must provide good ionizing radiation (i.e. in the 
300 KeV to 3 MeV range). In practice this means using 
either an o emitter or medium to high energy B emitter.' 
Although few o emitters are available for therapeutic use 
('At is an exception), a fair number off emitters, includ 
ing 'I, are currently receiving attention as possible candi 
dates for RIT. Among the more promising, are 'Re (t=90 
h, 'Cu (t=58.5 h), and 'Y (t=65 h). Of these, 'Y is 
currently considered the best,' with an emission energy 
of 2.28 MeV, it is calculated to deliver roughly 3 to 4 times 
more energy (dose) to the tumor per nanomole than either 
Re or 'Cu. Unfortunately, at the present time, good 
immuno-compatible chelands exist for only 'Re and 'Cu: 
The former may be attached using the same ligands as were 
developed for '"To," and the latter via the rationally 
designed activated porphyrins developed by Prof. Lavallee 
of Hunter College and the Los Alamos INC-11 team.' 
Although these new porphyrin-based systems, in particular, 
show real promise, being apparently far superior to the 
existing DTPA or DOTA-type systems,' further benefits 
should be derived from a bifunctional conjugate which is 
capable of forming stable, nonlabile complexes with 'Y' 
(which cannot be done with porphyrins). The texaphyrin 
ligand of the present invention not only forms stable com 
plexes with In" but also binds Y" effectively. A texaphyrin 
type bifunctional conjugate should be developed for use in 
'In-based RID and could also find important application in 
'Y-based RIT. This application outlines ways in which such 
putative bifunctional conjugates may be prepared. 
The observation that complexes of both Y" and In" may 
be prepared augurs well for the use of texaphyrin-type 
systems as conjugates in immunological applications: Both 
'Y and 'In could conceivably be attached to an antibody 
of choice using a functionalized texaphyrin. In this regard it 
is important to note that both the Y" and In" complexes of 
texaphyrin are formed rapidly (insertion and oxidation times 














precursor, and are hydrolytically stable in 1:1 methanol 
water mixtures (the half-lives for decomplexation and/or 
ligand decomposition exceed 3 weeks in both cases. 
A further advantage of having developed or developing a 
wide variety of solubilized texaphyrins, such as those shown 
in FIG. 31A, FIG.31B, FIG. 31C, and FIG. 27A, FIG. 27B, 
FIG. 27C, and FIG. 27D is that many of these would be 
suitable for further functionalization. For instance, treatment 
of texaphyrins 7 or 26, with thionyl chloride or p-nitro 
phenol acetate would generate activated acyl species suit 
able for attachment to monoclonal antibodies or other bio 
molecules of interest. Alternatively, standard in situ coupling 
methods (e.g. 1,1'-carbonyldiimidazole (CDI)') could be 
used to effect the same sort of conjugation. In either case, the 
ability to attach and deliver a potent photosensitizer directly 
to a tumor locus could have tremendous potential benefit in 
the treatment of neoplastic disorders. In addition, it is 
precisely this approach which will allow a variety of useful 
radioisotopes such as 'Y and 'In to be attached to a 
monoclonal antibody. This could prove to be of immense 
benefit in the development of this important approach to 
tumor detection and treatment. 
Literature citations in the following list are incorporated 
by reference herein for the reasons cited. 
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We claim: 






wherein M is a divalent metal ion and n is 1, or M is a 
trivalent metal ion and n is 2. 
2. A compound having the structure 
r 
wherein the substituents R, R2 and R are separately and 
independently selected from the group consisting of H, 
alkyl, amino, hydroxy, alkoxy, carboxy, carboxyalkyl, car 
boxamide, ester, amide, polyether, sulfonato, nitro, halide 
other than iodide, substituted alkyl, substituted ester, sub 
stituted ethers, and substituted amide; 
R and Rs are separately and independently selected from 
the group consisting of H, alkyl, amino, hydroxy, 
alkoxy, carboxy, carboxyalkyl, carboxamide, ester, 
amide, polyether, sulfonato, nitro, halide other than 
iodide, substituted alkyl, substituted ester, substituted 
ethers and substituted amide or together form an alk 
enylene bridge of the formula -C(R)=C(R)- 
CH=CH-; 
where R and R are separately and independently 
selected from the group consisting of H, alkyl, 
amino, hydroxy, alkoxy, carboxy, carboxyalkyl, car 
boxamide, ester, amide, polyether, sulfonato, nitro, 
halide other than iodide, substituted alkyl, substi 
tuted ester, substituted ethers and substituted amide, 
M is H, a di- or trivalent metal cation; and 




3. A compound having the structure: 
OC 
4. A compound according to claim 2 wherein at least one 
of R, R2 and R is other than methyl or au least one of R 
and R is other than H. 
5. A compound according to claim 2 having the following 
Structure 
f 
6. A compound according to claim 5 wherein each of R 
and Rs is methyl; or R is H and Rs is selected from the 
group consisting of methyl, methoxy, halide other than 
iodide, nitro, Sulfonato, -COOH, and 
-O(CH2CH2O)2CH, or R and Rs together form an alk 
enylene bridge of the formula -CH=CH-CH=CH- or 
-C(SO)=CH-CH=CH-. 


















8. A compound according to claim 7 wherein each of R 
and Rs is independently H or methyl, or R and Rs together 
form an alkenylene bridge of the formula -CH=CH 
CH=CH 
9. A compound according to claim 2 wherein M is a 
divalent metal ion selected from the group consisting of 
Cd, Zn'?, Hg, Mn"?, Ca"?, Co, Ni, Smt?, and 
UO'; and n is 1. 
10. A compound according to claim 2 wherein M is a 
trivalent metal ion selected from the group consisting of 
Nd", Sm', Eut, Gd, La", Lu, Y+ s In 3, Mnt, Co", 
Ni, Pr", Tb, Dy", Er", Tm, Yb", and U"; and n is 
2. 
11. A compound according to claim 5 wherein M is a 
divalent metal ion selected from the group consisting of 
Cd'?, Zn, Hg2,Mn2, Cat?, Co, Nit?, Smt and UO2: 
and n is 1. 
12. A compound according to claim 5 wherein M is a 
trivalent metal ion selected from the group consisting of 
Nd", Sm", Eu3, Gd, La", Lu", Y+3, Int3, Mn", Co., 
Ni, Pr", Tb, Dy", Er", Tm, Yb", and U"; and n is 
2. 
13. A compound according to claim 5 wherein R is 
hydrogen, Rs is -COOH, M is In", and n is 2. 
14. A compound according to claim 13 wherein the 
indium is '''In. 
15. A compound according to claim 5 wherein R is 
hydrogen, Rs is -O(CH2CH2O),CH, M is Gd' or Lu", 
and n is 2. 
16. A compound according to claim 2 wherein M is a 
paramagnetic ion. 
17. A compound according to claim 2 wherein M is a 
diamagnetic ion. 
18. A compound according to claim 5 wherein M is a 
paramagnetic ion. 
19. A compound according to claim 5 wherein M is a 
diamagnetic ion. 
20. A compound according to claim 16 wherein the 
paramagnetic ion is Gd". 
21. A compound according to claim 17 wherein the 
diamagnetic ion is In", Zn, Cd', La', or Lu'. 
22. A compound according to claim 1 wherein M is a 






Cd"?, Zn"?, Hg", Mn2, Ca2, Co?, Nit2, Sm', and Nd", Sm', Eu, Gd, La, Lu", Y+3, In", Mint, Coi, 
UO,'; and n is 1. Ni, Pr", Tb3, Dy, Er, Tm, Yb", and U"; and n is 
2. 
23. A compound according to claim 1 wherein M is a 
trivalent metal ion selected from the group consisting of ck k k k k 
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